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“Bilbo: Can you promise that I will come back?  
Gandalf: No. And if you do... you will not be the same.”
–
The Hobbit: An Unexpected Journey (2012) 
conversation between Bildo and Gandalf  
before Bilbo embarks on this adventure
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Proteins are fascinating, large, complex molecular machines that have developed 
over millions of years of evolution. Without proteins, life as we know it would not 
exist. Proteins are the work horses of the body. Antibodies recognize and bind 
to viruses or bacteria to protect the host. Enzymes trigger chemical reactions 
and assist in chemical processes. Messengers signal between cells. Structural 
components provide structural integrity and support for cells. Transport proteins 
assist in carrying chemical elements and molecules in and to other cells. Proteins 
are responsible for the structure, function, and regulation of all critical processes 
in every form of life. Life, however, is faced with constant selective pressures. 
These selective pressures are the drivers of natural selection. Given enough time 
and iterations, they lead to diversification of species in a process that is called 
evolution.1 Evolution on a molecular level occurs in the form of mutations that 
could have a structurally altering effect on proteins. Protein structural changes 
can directly affect the protein function. These changes are damaging when they 
drastically disrupt the protein function and can result in reduced fitness, disease, 
or, death of the host. Selective pressures favour changes that lead to higher fitness. 
Most variations are neutral to fitness,2 which resulted in the evolution of many 
‘optimally enough’ proteins suited for a certain task. Identifying which changes 
are neutral and which are damaging is one of the key challenges in modern-day 
genetics and also the main motivation for this thesis.
The completion of the Human Genome Project in 2003 gave a boost to the now 
approximately 22,300 protein-coding genes that have been identified in humans.3–5 
In the almost two decades that followed, a massive accumulation of human genetic 
data have become publicly available.6 These genetic data have allowed scientists 
to look at a fine scale of possible variations to protein-coding genes within a single 
species. Of all disease-causing genetic variation discovered to date, 58% alters or 
impairs the protein structure.7 The accumulation of genetic information from a 
multitude of human individuals have led to notions of ‘tolerated genetic variation’: 
variation that occurs in high-frequency in the general population and are therefore 
likely harmless.8–11 
Despite these vast resources, it remains a challenge to predict if genetic variation 
is damaging. Small changes in the genome can have a major effect on a protein’s 
structure and thus function. To begin to understand why, it is crucial to first learn 




What makes a protein?
Proteins consist of hundreds to thousands of smaller units called amino acids. 
All amino acids contain an amino (NH2) group and a carboxyl (COOH) group. 
The amino group can bind via a peptide bond to the carboxyl group of another 
amino acid to form a dipeptide.  To form a protein, multiple amino acids are 
chained together in a polypeptide. The first residue in a polypeptide is called the 
N-Terminus, and the last residue is called the C-Terminus. When represented 
in the form of letters a polypeptide is called a protein sequence, or the primary 
protein structure (Figure 1).12
There are 22 different proteinogenic amino acids, each commonly denoted by a 
unique 1-, or, 3-letter combination (A/Ala, C/Cys, D/Asp, E/Glu, F/Phe, G/Gly, H/
His, I/Ile, K/Lys, L/Leu, M/Met, N/Asn, O/Pyl, P/Pro, Q/Glu, R/Arg, S/Ser, T/Thr, U/
Sec, V/Val, W/Trp, Y/Tyr). Every amino acid has the same neutral backbone and a 
characteristic side-chain (or R-group). The side-chain determines the amino acid 
type and has a unique set of different structural and chemical properties.
The importance of side-chains
The side-chains determine the amino acid type. The properties of side-chains 
shape the protein, and these properties can be of structural or chemical nature. 
These properties play an especially important role in the folding of the primary 
protein structure into a tertiary structure. Side-chain features that are particularly 
important for the structural formation or function of the protein are the size, 
electrical charge, presence of a reactive sulphur atom, ability to form salt bridges, 
overall atomic rigidity, and, hydrophobicity.
















































Protein folding is the process in which a polypeptide chain conforms into a 
3-dimensional molecule: the tertiary structure. The tertiary structure shape is 
determined by the environment and the chemical and structural properties of 
amino acids in the polypeptide. The tertiary protein structure consists of three 
generic patterns, α-helices, β-sheets, and, loops. These generic patterns are called 
secondary protein structures (Figure 2A). The type of secondary protein structure 
is influenced by the forming of hydrogen bonds between amino acids. α-helices 
are right-hand-coiled structural conformations that consist of a multitude of 
repetitive patterns: four amino acids, wherein each first and last residue forms a 
hydrogen bond using their backbone. β-sheets consists repeated stretched of 3 to 
10 amino acids, called β-strands, that are interconnected via hydrogen bonds and 
assisted by loops and turns.
The tertiary protein structure (Figure 2B) is the native conformation of a single 
polypeptide chain. If multiple polypeptide chains are involved to form a shared 
conformation, it is called a quaternary protein structure (Figure 2C). In the 
components of the quaternary protein structure are not held together by covalent 
bonds. Instead they are bound by hydrophobicity, salt bridges, or, disulphide 
bridges, to name a few. The forming of a quaternary protein structure is also 
directly influenced by the side-chain properties of the amino acids. Quaternary 
protein structures that are formed by multiple proteins are commonly referred 
to as polymers, with 1 = monomer, 2 = dimer, 3 = trimer, etc. And, in the case of 
dimers or larger polymers, homo- or hetero- prefixes indicates if the quaternary 
structure is made from identical (homo) or different (hetero) polypeptides. In 
Figure 2C an example of a homo-tetrameric protein structure is provided. In this 
tetrameric conformation, four identical protein structures join together to form 
the pore-like structure necessary for channelling K+ ions. All of the structural 
examples in Figure 2 are taken from a mammalian voltage-gated K+ channel in 
an inactivated state (PDB: 5WIE13). This particular protein structure was used to 
model and analyse mutation hotspots in Chapter 6. 
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How does the genome relate to the protein structure?
The genome is the collection of all genetic information necessary for the building, 
maintaining, and, reproduction of organisms. It is passed from parents to offspring. 
In cellular organisms, like humans, every cell has a copy of the genome. The 
genome is contained in multiple large molecules that are called chromosomes. 
The chromosomes are composed of Deoxyribonucleic acid (DNA) molecules. DNA 
consists of even smaller molecules called nucleotides which are chained together 
in the shape of a double helix. There are four different nucleotides (A, C, T, G) 
and each nucleotide is paired with another nucleotide to form base pairs that 
constitute the double helix shape.15 Similar to the primary protein structure, 
where the sequence consists of amino acids, the DNA can be represented as 
a sequence of letters corresponding to the nucleotides. The human genome 
consists of 23 chromosome pairs, totalling to 46 chromosomes. Half of these 
are inherited from the father and the other half from the mother. Combined, the 
chromosomes contain approximately 6 billion base pairs. Potentially, a change 
to any one of these 6 billion base pairs can influence the entire organism. In 
the human genome most of the essential information is located in regions that 
are called genes. A recent assessment of the human genome identified 60,669 
different genes, of which 32.9% are protein-coding, 42.1% non-coding RNA genes, 
and, 24.3% pseudogenes.16 The protein-coding genes make up roughly 1-2% of 
the entire genome.3 They encode the amino acid arrangement of every protein in 
human cells.
Protein-coding genes are blueprints
Protein-coding genes describe how to construct a primary protein structure via 
sets of instructions. These genes ensure the consistency of how proteins are 
composed throughout all cells of an organism. The genomic structure of protein-
coding genes in eukaryotes consists of regulatory sequences and the open reading 
frame. The regulatory sequences consist of enhancers, silencers, promoters 
and the 5’ and 3’ untranslated regions (UTR). These parts of the protein-coding 
genes primarily regulate the expression level of proteins. Additionally, they 
contain instructions for isoforms in the form of transcripts. These isoforms are 
alternative protein sequence conformations. According to GENCODE there are 
84,068 possible transcripts for the 19,959 curated human protein-coding genes 
(GENCODE Release Version 34).16 In theory, these transcripts could each result 
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in a different protein sequence. However, most differences between transcripts 
are in the non-coding UTR regions and will therefore not affect the final protein 
sequence.17 
The open reading frame is composed of regions called introns and exons. Introns 
are non-coding and important for isoform formation and the protein expression 
level. Exons code for parts of the amino acid sequence via triplets of nucleotides 
called codons. Each codon directly correspond to one of 20 amino acids or indicate 
the termination of the coding region via a ‘stop-codon’.18 The amino acid sequence 
is constructed from a protein-coding gene with three steps called “central dogma 
of molecular biology”. Protein folding could be seen as the final step (Figure 3):19
1. Transcription: The 5’UTR, the introns and exons and 3’UTR are transcribed 
into precursor messenger RNA (pre-mRNA). In this step DNA, with the 
help of ribosomes, is copied into an RNA representation.
2. Post-transcriptional modification: The intronic regions are removed from 
the pre-mRNA, this way the exons form the complete, untranslated, 
protein sequence in RNA, which is called mature messenger RNA (mRNA). 
3. Translation: the mRNA is translated into a chain of amino acids (a 
polypeptide). 
4. Protein folding: The polypeptide chain conforms into the tertiary protein 
structure.
How can changes in the genome affect proteins?
Genetic variations are alterations to the nucleotide mark-up of the genome. These 
variations can affect only one nucleotide (e.g. transitions), one or a stretch of 
nucleotides (e.g. insertions and deletions also called indels, or substitutions), or 
affects a region of nucleotides (e.g. structural variations). Structural variations can 
be deletions, insertions, inversions, duplications, or, copy number variations. If 
any of these variations occur within the region of a protein-coding gene, they may 
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Most of the work in this thesis is focused on single nucleotide variants (SNVs) that 
occur within protein-coding regions. There again is specific jargon for different 
SNVs. If an indel SNV in the coding region affects the reading frame of codons 
it is called a frameshift variation, and, can result in an entirely different protein 
sequence. Substitution SNVs can have multiple effects on the protein. If the 
substitution does not change the amino acid translation it is called synonymous, 
otherwise it is called missense. When the translation is changed to a stop codon, it 
is called nonsense or stop-gained (Table 1). Nonsense and missense variants are 
also referred to as non-synonymous variations. 
Table 1. Example of single nucleotide variants in codons and the effect on encoding. (Structural 
formula representations courtesy of NEUROtiker, adapted from Wikimedia and are licensed under 
public domain).
How genetic variations in protein-coding genes can result in disease 
The amino acid composition of proteins is encoded in protein-coding genes, and, 
therefore, the genetic code plays an important role in dictating the composition of 
a protein. Genetic variations may affect proteins in a positive, neutral, or, negative 
way. Positive and negative changes can alter the protein in a loss-of-function 
(LoF) or a gain-of-function (GoF) effect. A variant with a negative effect is called 
damaging or deleterious. If the damaging variant leads to disease, it is called a 
pathogenic or disease-causing mutation. 
Nonsense variants generally have the largest effect on the protein structure. 
These variants induce the termination of the open reading frame. The result 
may be a partial structure, that is often ‘cleaned up’ by a process called nonsense 
mediated decay (NMD). If the partial protein is cleaned up by NMD there is no 




the dosage. Disease may occur due to this lack of dosage, and, if this is the 
case, the mechanism of disease is called haploinsufficiency (HI). The effect of a 
missense variant greatly depends on the location of that variant in the protein 
structure and the difference between the original amino acid residue and the 
one it changes into. If the residue introduced disrupts the folding of the protein 
structure, the structure could also be cleaned up in the NMD process. Therefore, 
missense variants may trigger a HI disease-mechanism. Alternatively, damaging 
missense variants that do not disrupt folding may still disrupt the function, or 
functional sites, of the protein. If this leads to disease, the disease-mechanism 
is called non-haploinsufficiency (NHI). Determining if variants are damaging, and 
how, can require the need for functional testing and replications studies, and, 
therefore is often a laborious task. In Chapter 4 and 6 we show that clustering of 
missense variants found in patient with neurodevelopmental disorders indicate a 
likely disease-mechanisms and help identify candidate disease-genes. 
Identifying genetic variations in a diagnostic setting
In the two decades following the completion of the Human Genome Project, 
the technology involved in analysing the human genome advanced immensely. 
The Human Genome Project provided the first version of the human reference 
genome.3,4 The reference genome can be used to identify genetic variation. Genetic 
variations are differences in nucleotide composition of a patient compared to the 
reference genome. To find these differences, whole exome sequencing (WES)21 or 
whole genome sequencing (WGS)22 can be used. A patent undergoing WES or WGS 
will result in many small genome sequence pieces that are called reads. These 
reads are then mapped to the reference genome. The total number of mapped 
reads at the same location indicates the quality and certainty of any genetic 
variants that are identified at that location. Nowadays, whole exome sequencing 
and whole genome sequencing are part of routine diagnostic protocols.23,24 Since 
the first version of the human reference genome, disease-gene associations have 
increased by a four-fold.25
The first step in a present-day genetic diagnostic procedure is to identify all 
genetic variation in a patient. The second step is variant effect prediction. In a 
diagnostic setting the goal for variant effect prediction is to find the variant, or 
variants, that explain the phenotype of the patient. Typically each sequenced 
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individual has between 20,000 and 26,000 genetic variants in the coding 
regions, which can be reduced to 150-500 candidate variants by various filtering 
strategies.26 This commonly includes considering variants that alter the protein-
coding region, are rarely encountered in the general population, are located in a 
previously disease-associated genomic regions, or, are present in genes that have 
a specific biological role. Computer-aided variant effect predictors have evolved 
over the last two decades as well. Deleteriousness predictors, such as SIFT27, 
Polyphen-228 and CADD29, make use of an aggregate of information resources 
and proven metrics to determine the likelihood of a variant to have a deleterious 
effect. HOPE30 attempts to explain the functional effect of a missense variant in the 
protein structure. Despite these predictors, it remains challenging to accurately 
diagnose patients. Another way to gather evidence for diagnosis is to combine 
genetic data from patients. In Chapter 5 we combined genetic data from 31,058 
patients with developmental disorders. By combining this data, we found 285 
genes significantly enriched with rare mutations. Of these, 28 genes were not yet 
associated to developmental disorders. 
What can we learn from evolution?
The selective pressures that drive evolution induce changes in the genome. These 
changes may have an effect on the protein structure and function. Given enough 
iterations these changes enable diversification into different species.31 The effects 
of evolutionary–driven genetic variations on genomes are an active topic for 
scientific studies. Changes that occurred only a short while ago, or hundreds, or 
millions of years ago can be traced back by sequence analysis. There are many 
ways to approach this resource of information. For example, these data help 
estimate how, and when exactly, species diversified by constructing genome-
based phylogenetic trees.32,33 From a shorter time-perspective these data help in 
uncovering history of human geological migration patterns.34 Or these data help 
explain why certain African populations carry a disease-enabling copy of the gene 
that causes cycle cell anaemia, as it offers protection against malaria.35
Genetic changes can be damaging, neutral, or, beneficial. There are many possible 
exceptions and it is difficult to identify which is which. The genome is so complex 
that not every change will have an everlasting negative or beneficial effect for the 




common way to predict likely damaging changes is by evolutionary conservation.36 
Evolutionary conservation can be computed by comparing lack of changes 
between highly similar proteins from different species.37 Popular pathogenicity 
predictors make use of evolutionary conservation (e.g. SIFT27, Polyphen-228 and 
CADD29). The underlying assumption of evolutionary conservation is that there 
are a great number of iterations needed to diversify into different species. If the 
residues at equivalent proteins rarely change during this diversification, then they 
are probably important. On the other hand, if these residues change often, they 
are likely neutral.
Highly similar sequences are necessary to compute evolutionary conservation. The 
de facto standard to find analogy in sequences is the basic local alignment search 
tool (BLAST).38 BLAST requires an input sequence and then scores sequences 
based on the similarity to that input sequence. Analogy is often an indication 
of homology. Similar sequences (>25% sequence identity) can indicate a shared 
evolutionary ancestor and are called homologous.37 Homologous relationships can 
accommodate the transfer of information, and help elucidate important residues 
and regions within sequences. Transfer of information can be achieved via 
sequence alignment or multiple sequence alignment (MSA). Sequence alignments 
are generally made on similar sequences via Clustal39. MSA allows nucleotides or 
amino acids to be aligned to corresponding positions (Figure 4A). In homologous 
proteins, mutations at corresponding locations across an MSA are known to result 
in similar effects.40
Evolutionary conservation can be calculated by considering the amount of different 
amino acids encountered. This is computed per column in an MSA, and preferably 
calculated over homologous protein sequences from evolutionary distant species. 
The result per position can be expressed as relative entropy37. Using relative 
entropy, in figure 4B, the letter-size indicates how conserved residues are based 
on the MSA from Figure 4A.






















































































































































































































 sequence logo generated via the Skylign tool 42 for the EG
F-like dom
ain (PF00008). The height of each residue is based on the 
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ultiple sequence alignm
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ple the big C’s correspond to highly conserved cysteines. The thin red vertical lines in the sequence logo denote regions prone to contain 
deletions and the orange lines are regions prone to insertions.































































































































































































































Protein domains and homology
Protein structure is more evolutionary conserved than sequence.44 The protein 
structure determines the function. Protein functions rely on elementary functional 
elements. These elements are for example the binding of an ion, voltage-gating, 
a specific structural shape, etc. These elementary functions have been optimized 
over the course of evolution. When these elements have a similar protein 
structure and/or sequence they are called protein domains. Protein domains can 
be detected from sequences by locating evolutionary conserved regions. When 
these evolutionary conserved regions have a similar sequence composition and/
or structure, then these often have the same function. When these regions are 
homologous, and can be located in multiple proteins, they can be part of a protein 
domain family.
The example in Figure 4 is an EGF-like domain (PF00008) that we analysed in-
depth in Chapter 2 of this thesis. This is a structural domain and most parts in 
this protein domain, from a sequence perspective, are variable (Figure 4B). The 
large C’s, however, indicate conserved cysteines. The structural importance of 
the conserved cysteines can be seen in Figure 4C as they form rigid disulphide 
bridges. In EGF-like domains, any changes to the conserved cysteines will cause 
loss of a stabilizing disulphide bond necessary for the structure of the domain.45 
Understanding the human genome from an evolutionary perspective 
The UniProt Knowledgebase (UniProtKB) currently contains 37,670 proteomes 
of which 1,832 are part of the Swiss-Prot collection that have been reviewed by 
experts (release 2020_03).46 Evolutionary conservation between-species can be 
computed from these data. This helps to discover homologous genes, proteins 
and protein domains. Most proteomes contained in the UniProtKB result from a 
single to a few sequencing samples. It will require considerably more sequencing 
efforts to analyse the within-species variability for each of these proteomes. 
For humans, however, sequence data is becoming more readily available. This 
is gradually leading to a more accurate estimation of within-human variation. 
Patients and controls involved in genetic studies can consent to their genetic 
data be used for scientific purposes. Contributing to the formation of large 
population-size catalogues of genetic variation.47–51 The largest dataset to date is 
gnomAD, representing 141,456 individuals.51 From these datasets, the frequency 
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of rare and commonly encountered genetic variations can be determined. These 
measurements have led to the notion of genetic tolerance. Genetic tolerance is a 
measurement from a within-species perspective, and, has a likeness to evolutionary 
conservation. However, it is different in that evolutionary conservation is based 
mostly on single sequence comparisons between related species. In genetic 
tolerance there are hundreds of thousands of sequences that we can compare 
from a single species. This abundance of data can uncover much finer details 
than ‘conserved’ versus ‘variable’. Genetic tolerance can indicate positions and 
regions that are highly variable or not variable at all. Genetic tolerance can help to 
determine the likely pathogenicity of genetic variants.26,52
In recent years, metrics such as RVIS8, subRVIS9 and pLI50 have been developed that 
provide an indication of potential deleteriousness of variants. Perhaps inspired by 
evolutionary conservation, these methods use the absence of population-based 
variation to determine variant deleteriousness. Genes vary in their tolerance to 
variation and this can be used to determine their essentiality.8 Regions within 
genes vary in tolerance to variation as well. Regions that are intolerant to variation 
correspond to important parts of the gene and disease variants are more likely 
found within these regions.9,10 For example, Figure 5 depicts a ‘tolerance landscape’ 
for the gene LMX1B created by our webserver MetaDome (Chapter 3). The regions 
that are intolerant to missense variants correspond to the protein domain regions 
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Scope of this thesis
In this thesis I have combined structural biology and human genetics. I integrate 
protein information with publicly available human genetic variation. This 
combination allowed validation of the following hypotheses:
Hypothesis I: The parts of a protein that are tolerant to population-based 
genetic variation are not important for protein function.
Hypothesis II: Genetic variants that are damaging to a part of a protein 
can be used to predict damaging effects in highly similar parts in other 
proteins.
Investigating these hypotheses led to integrate human genetic data with protein 
domain and protein structure information. This combination resulted in the 
following chapters.
Meta-domains and the MetaDome web server
Integrating human genome data with homologous protein domains resulted in 
meta-domains (Chapter 2). Meta-domains allow transfer of information between 
equivalent residues in different protein domains. This transfer of information helps 
interpret genetic variation. The meta-domain concept has been implemented in 
the MetaDome web server (Chapter 3).
Clustering of de novo missense mutations suggest disease mechanisms
De novo mutations (DNMs) are rare genetic variants. In patients with developmental 
disorders (DD), DNMs are the likely cause. We identified that missense DNMs 
clustered in 15 genes in publicly available DD patient data (Chapter 4). Of these, 
3 genes were novel DD-associations. Analysis of these clusters in the protein 3D 
structure suggest an N-HI disease-mechanism.
Deleterious de novo missense mutations locate to protein domains
We formed the largest cohort to date of DNMs identified in 31,058 DD-patients 
(Chapter 5). We found 285 genes significantly enriched with DNMs. Of these, 28 
genes were novel DD-associations. Specifically, I showed that missense DNMs are 
more likely located in protein domains. This is not the case for stop-gained and 
synonymous DNMs. Furthermore, specific protein domain families are enriched 




Gene DD-association based on a single de novo mutation
I combined meta-domains (Chapter 2) with the insights that missense DNM 
clusters indicate disease-mechanisms (Chapter 4), and, that protein domains 
are enriched with missense DNMs (Chapter 5). This led to the identification 
of missense DNM hotspots in meta-domains (Chapter 6). The hotspot DNMs 
were located in 25 genes. Analysis of these hotspots in the protein 3D structure 
confirmed deleteriousness. Six of these genes are novel candidate DD-associations 
based on a single DNM in a hotspot.
In Chapter 7 I discuss the limitations and implications of this thesis.

2Chapter 2Aggregation of population-based genetic variation over protein domain homologues and its potential use in genetic diagnostics
Laurens van de Wiel, Hanka Venselaar, 
Joris A. Veltman, Gert Vriend, and Christian Gilissen
Published in Human Mutation




Whole exomes of patients with a genetic disorder are nowadays routinely 
sequenced but interpretation of the identified genetic variants remains a major 
challenge. The increased availability of population-based human genetic variation 
has given rise to measures of genetic tolerance that have been used, for example, 
to predict disease-causing genes in neurodevelopmental disorders. Here, we 
investigated whether combining variant information from homologous protein 
domains can improve variant interpretation. For this purpose, we developed a 
framework that maps population variation and known pathogenic mutations onto 
2,750 “meta-domains.” These meta-domains consist of 30,853 homologous Pfam 
protein domain instances that cover 36% of all human protein coding sequences. 
We find that genetic tolerance is consistent across protein domain homologues, 
and that patterns of genetic tolerance faithfully mimic patterns of evolutionary 
conservation. Furthermore, for a significant fraction (68%) of the meta-domains 
high-frequency population variation re-occurs at the same positions across domain 
homologues more often than expected. In addition, we observe that the presence 
of pathogenic missense variants at an aligned homologous domain position is 
often paired with the absence of population variation and vice versa. The use of 
these meta-domains can improve the interpretation of genetic variation.
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Next generation sequencing technologies now allow for the comprehensive 
identification of all genetic variation in an individual, and exome and genome 
sequencing are increasingly being used in clinical care to provide a diagnosis for 
patients with a genetic disorder.23,24 The interpretation of the large number of 
genetic variants present in the exome or genome of a patient is now the major 
remaining challenge.26 Filtering strategies that reduce the number of candidate 
disease-causing variants make use of information such as the occurrence of 
variants in the normal and in the diseased population, knowledge about the role 
of genes in disease, and the predicted effect of specific mutations.30 Algorithms 
such as Polyphen-228 and CADD29 are able to predict the pathogenicity of individual 
variants, but leave room for improvement, especially within a clinical context.55–57 
Other methods have used population-wide genetic variation from healthy 
individuals that is available in large public databases such as the NHLBI Exome 
Sequencing Project (ESP),58 and the Exome Aggregation Consortium (ExAC)50 to 
construct metrics that estimate the genetic tolerance of a gene. Various studies have 
shown that genetic intolerance of a gene is a strong indicator for a role in severe 
human diseases such as intellectual disability and other neurodevelopmental 
disorders.8,59 Metrics such as RVIS8 and pLI50 are now being used in conjunction 
with variant pathogenicity prediction algorithms to improve the interpretation of 
variants of unknown significance in patients suffering from these disorders.
The continuous growth of catalogues of human genetic variation has made it 
feasible to investigate genetic tolerance at a finer scale, such as for individual 
exons of a gene or even domains of a protein. This was done, for example, by 
Gussow et al.9 who developed subRVIS and found that tolerance within a gene 
varies, and that specific protein domain coding parts of a gene are sometimes 
much more intolerant than the whole gene. Moreover, the authors found that 
intolerance to genetic variation within genic sub-regions significantly correlates 
with reported pathogenic mutations. These patterns of region-specific variation in 
genetic tolerance were also used by Ge et al.10 to detect missense-depleted regions 
to confirm the pathogenicity of individual variants of unknown significance. 
Since its introduction, one of the applications of BLAST38 was to identify 
homologous proteins. Mutations at corresponding locations in these homologues 
were found to result in similar effects on protein stability.40 Protein domains are 
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especially interesting as they have homologous relationships spanning many 
proteins. Because of this, protein domains can also have many homologues 
that occur within the same species. An example of a framework that annotates 
protein domains to proteins is Pfam.41 The Pfam database is a large collection of 
protein domain families represented by curated multiple sequence alignments 
(MSAs) and a hidden Markov model (HMM). In recent work Miller et al. combined 
mutation information from different protein domain homologues to identify 
mutation hotspots in cancer, and Melloni et al. used a similar approach to identify 
cancer driver mutations.60,61 We hypothesized that genetic tolerance found in 
the regions coding for protein domains, may be consistent across other within-
human homologues of that domain and that therefore interpretation of variants 
in a protein domain can be improved by aggregating population variation over 
homologous protein domains.
Materials and Methods
Mapping of human genomic variation to Pfam domains
We performed a Protein-Protein BLAST 2.2.31+62 for each of the longest 
translations for all 18,651 human protein-coding genes in the GENCODE Basic set 
release 19 GRCh37.p1363 to canonical and isoform human protein sequences in 
UniProtKB/Swiss-Prot Release 2016_09 (Swiss-Prot).64 We then selected the top 
BLAST result with 100% identity to the query sequence and a BLAST E-value of 0.01 
or less. Pfam-A 30.041 protein domains in the matched Swiss-Prot sequences were 
annotated using InterProScan 5.20-59.0.65 ClustalW2 v2.139 was used to create 
pair-wise alignments between the gene translations and Swiss-Prot sequences. 
The resulting alignment was then used to map genomic variation onto residues in 
Swiss-Prot protein sequences.
Datasets of population genetic variation and disease-causing 
missense variants
Population variation was obtained from the Exome Aggregation Consortium 
(ExAC) v0.3.150 by selecting all synonymous and missense variants with the PASS 
filter criteria. For the creation of meta-domains we considered missense variants 
from ExAC with an allele frequency > 0.1%. For validation purposes we also used 
two additional sets of ExAC missense variants having >0.5% and >0.05% allele 
frequency.
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We selected a set of disease-causing missense variants from the Human Gene 
Mutation Database (HGMD) 2016.266 that have disease-causing (DM) status, which 
were subsequently filtered by removing all variants that are identical to PASS 
variants in ExAC with >0.1% allele frequency. This filtering reduced the original set 
of HGMD DM missense variants by 0.17%. In addition, we used missense variants 
from ClinVar (downloaded for GRCh37 on 2017-06-15), with disease-causing 
(Pathogenic) status, as an additional validation to HGMD DM variants. The filtering 
of identical PASS variants in ExAC with >0.1% allele frequency, that was used for 
the HGMD DM set, was applied to this set as well.
Aggregation of genetic variation into meta-domains
In order to aggregate genetic information over protein domain homologues we 
considered each Pfam identifier found in more than one gene as a within-human 
homologue. In this study, when we mention homologous protein domains, or 
domain homologues, we refer to Pfam protein domains that are homologous in 
the protein-coding regions of the human genome. For each domain found this 
way, we retrieved the Pfam HMM and the domain protein sequence. We used all 
the domain sequences that had the same Pfam identifier, together with the Pfam 
HMM, to generate a MSA using the HMMER 3.1b2 tool.67 We used our mapping 
to combine genetic variants on positions that were aligned to the same Pfam 
domain positions. Variations on Swiss-Prot residues in insertions with respect to 
the Pfam domain were ignored. The percentage of homologous domains aligned 
to a position (MSA coverage) was determined based on the number of gaps with 
respect to the Pfam domain.
Gene Ontology Biological Process enrichment analysis in protein 
domains
Gene Ontology Biological Process (GOBP) enrichment analysis was performed 
using the R package dcGOR 1.0.6.68
Computing genetic tolerance via the missense over synonymous 
ratio
We use the non-synonymous over synonymous ratio, or dN/dS score, to quantify 
genetic tolerance in genes and domains. In our setting this score is based on 
the single nucleotide missense and synonymous variants (SNVs) from ExAC in a 
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protein-coding region (missenseobs and synonymousobs). This score was corrected for 
the sequence composition of the protein coding region based on the total possible 
missense and synonymous SNVs (missensebg and synonymousbg):
Consistency of genetic tolerance across protein domain homologues
We calculated the Median absolute deviation:  
|) to measure whether genetic 
tolerance scores are consistent across homologous domains. For each domain 
occurrence ‘xi’ of a homologous domain group ‘x’ we calculate the difference of 
dN/dS score to the median. The median of all these differences is then computed as 
the MAD. The minimal and optimal value of the MAD score is zero, meaning that no 
score deviates from the median. To test whether the MAD score per homologous 
domain group is significantly different from another randomly selected group 
of homologues, we permuted the MAD scores for each homologous domain 
group using the dN/dS score of each member in that group and comparing it to 
the median dN/dS of another homologous domain group that we selected via 
the numpy function random.permutation in Python. This permutation test was 
repeated 10,000 times.
Evolutionary conservation and population variability
We measured sequence conservation via the relative entropy per position37 in a 
multiple sequence alignment (MSA) to compute the evolutionary conservation 
and population variability: . Here ‘j’ is an aligned 
position, ‘R’ is the amino acid residue type, ‘ ’ is the frequency of how often 
a residue of type ‘R’ occurs at position ‘j’. The relative entropy ranges from 0.0 
to 1.0 for conserved to variable. We used the Pfam-A full alignment for each 
Pfam domain to compute evolutionary conservation. We used our mappings to 
assess population variability by extracting missense and synonymous variants 
and their respective allele frequencies from ExAC to compute the ‘ ’ variable. 
To achieve a sufficiently high MSA resolution and certainty of correct entropy we 
only con-sidered positions for computing the relative entropy that had at least 25 
sequences with 80% MSA coverage.
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Quantifying patterns of missense variants in meta-domains
We created a metric to quantify how often a consensus position in a meta-
domain contains identical missense variants (i.e. two or more homologous 
domains wherein the aligned residues both are identical in reference and 
alternative amino acid residues). We call this metric the characteristic missense 
variant score: . Here ‘Lx’ is the size of meta-domain ‘x’, ‘j ’ is an 
aligned domain position, ‘ ’ are the number of missense variants found in all 
domain homologues aligned to position ‘j ’ and ‘ ’ are the number of missense 
variants in ‘ ’ that are of identical change in amino acid (i.e. that have identical 
reference residues and change to the same alternate residue). The  
normalizes the CMVS with respect to the domain size.
We assigned values of significance to patterns of missense variants observed in 
meta-domains by comparing these to permuted meta-domains resulting from 
Monte Carlo experiments. In these experiments we shuffled missense variants 
in each domain occurrence ‘xi’. To perform this shuffling, we first estimated the 
probability of a missense variant to occur in ‘xi’ via  , where ‘
’ are the number of aligned residues and ‘ ’ are the number of missense 
variants found in domain ‘xi’. Then we estimated the probability for any missense 
variant to occur on an aligned position ‘j’ by considering the codon of that position 
with respect to the codon table: . Finally, we distributed 
missense variants on the domain occurrence by combining these two probabilities 
and assessing each possible missense variant. The distribution of missense 
variants was subsequently used to reconstruct a permuted meta-domain over 
1,000 experiments for each meta-domain.
The patterns of missense variants across homologues were then tested for 
significance in two different ways. First we computed per aligned position the ratio 
of missense variants observed in contrast to the number of domain occurrences 
aligned. We checked if a position is significantly enriched for either the reference 
allele or the missense variant allele as compared to the same position in the 
permuted meta-domains. We report the meta-domains for which more than 75% 
of the positions are significantly different from the permuted meta-domains. 
Secondly, we tested whether the entire meta-domain is significantly enriched 
for identical variants via NCMVS as compared to the permuted meta-domain. In 
both cases we made our comparisons with the Welch’s t-test and used Bonferroni 




In total 16,684 GENCODE genes were mapped to Swiss-Prot protein sequences 
and annotated with protein domains from Pfam (Methods). We found 5,250 Pfam 
domains spanning 33,638 domain occurrences in these genes, of which 30,853 
made up 2,750 within-human Pfam domain homologues (Supp. Table S1). We 
found 961 Pfam domain homologues to occur in exactly two different genes and, 
on average, a within-human homologous protein domain occurs in at least six 
different human genes. The most prevalent domains were the “KRAB domain” 
(PF01352), “Zinc finger, C2H2 type” (PF00096) and “Protein kinase domain” 
(PF00069), each being present in more than 300 different human genes. Pfam 
protein domains covered approximately 41% of coding sequences of the 16,684 
genes. In total 1,493,414 synonymous, 2,892,092 missense variants from ExAC, 
58,968 DM missense variants from HGMD, and 14,016 Pathogenic missense 
variants from ClinVar are present in the coding regions of our set of genes. 71% 
of disease-causing missense variants from HGMD and 72% pathogenic missense 
variants from ClinVar occur in Pfam domain regions (Supp. Table S2). 
Tolerance to genetic variation of protein domains
Regions that code for protein domains are sometimes much less tolerant than 
the whole coding region of a gene.9 Therefore, we first wanted to test how similar 
tolerance patterns in protein domains are to their respective genes. We used the 
population-based variation from ExAC to compute the ratio of missense over 
synonymous variants (dN/dS). This, we used as a measure of genetic tolerance 
scores for all genes and Pfam domains (Supp. Data S1 and S2; Methods). We 
compared the tolerance measured in genes of different gene sets that are 
known to have a particular pattern of genetic tolerance,59 to the tolerance of the 
regions with protein domains in these genes. We found that protein domains in 
genes known as intolerant, such as housekeeping genes69 and genes involved 
in neurodevelopmental disorders,70 are indeed intolerant too (Welch’s t-test 
p=4.33e-61 and p=5.24e-57 respectively; Supp. Table S3, S4). Conversely, we 
found that domains in genes that are known to be tolerant to protein truncating 
variation and variation in general71 are also tolerant to missense variation (Welch’s 
t-test p=7.42e-23; Supp. Table S3 and S4; Figure 1a and 1b). Thus we find that 
protein domains have a similar trend of tolerance as their genes. 
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After establishing that genetic tolerance of a domain mimics that of its respective 
gene we wondered whether dN/dS scores are consistent across domain homologues. 
We used the Median Absolute Deviation (MAD) computed over the homologues 
of a domain to test for the consistency of genetic tolerance (Supp. Data S3; 
Methods). We find that 2,741 out of 2,750 (99%) aggregated homologues show a 
consistent pattern of dN/dS scores as compared to what may be expected by chance 
(Welch’s t-test p<0.05, Bonferroni corrected; Methods; Supp. Table S5; Figure 1c). 
The most consistently intolerant domain was the “SRF-type transcription factor 
(DNA-binding and dimerisation domain)” (PF00319) whereas the “Keratin, high-
sulphur matrix protein” (PF04579) is the most consistently tolerant domain (Supp. 
Table S6, S7). These results show that domains have tolerance patterns that are 
consistent over homologues, and thus that genetic variation in one protein domain 
is therefore not fully independent from the variation measured in the homologues 
of that domain. This potentially allows us to aggregate variant information across 
protein domain homologues.
Interestingly, enrichment analysis for Gene Ontology Biological Process (GOBP) 
on the top 5% of most intolerant domains (n = 134) found that these are strongly 
enriched for biological processes such as chromatin condensation, chromosome 
organization and DNA packaging (p=5.90e-08, p=7.10e-05, p=1.10e-05 respectively, 
Supp. Data S4). This connection to chromatin remodelling has also been observed 
among dominant genes for neurodevelopmental disorders.72–74 
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◀ Figure 1. Tolerance in genes, domains and domain homologues
A.) Tolerance to normal genetic variation as measured via the dN/dS ratio (Methods). A higher 
dN/dS ratio means that the gene is more tolerant to genetic variation and vice versa. From left 
to right data is presented for all 16,684 genes (blue), 398 genes involved in neurodevelopmental 
disorders (green),70 361 housekeeping genes (red),69 157 loss-of-function tolerant genes (purple).71 
All groups are significantly different (Supp. Table S3). B.) As A. with the exception that the dN/dS 
ratio is now computed only for domain regions. All 33,638 domains (blue), 1,302 domains in genes 
involved in neurodevelopmental disorders (green), 811 domains in housekeeping genes (red), 358 
domains present in loss-of-function tolerant genes (purple). All groups are significantly different 
(Supp. Table S4). C.) The consistency of dN/dS scores across homologous domains computed via 
the MAD of the dN/dS (Methods). The lower the MAD score the more consistent is the dN/dS ratio. 
There are 2,750 Pfam domains that have homologues in our set of genes with a total of 30,853 
occurrences (blue). Of the Pfam domains, 383 have a homologue occurring in a gene involved 
in neurodevelopmental disorders (green), 223 have a homologue occurring in a housekeeping 
gene (red), and 178 have a homologue occurring in a loss-of-function tolerant gene (purple). 
The permuted domains (yellow) consists of 27,500,000 permutated MAD scores that resulted by 
computing the MAD score using the median dn/d of another Pfam domain (Methods). All groups 
have been found significantly different from the permuted domain group (Supp. Table S5). The 
impact of different domain sizes on the MAD score is minimal (Supp. Figure S5 and S6).
Population variability across domain homologues mimics 
evolutionary conservation
Although many methods have made use of population-based genetic variation 
to assess genetic tolerance, it has remained unclear to what extent population 
variability complements information from evolutionary conservation. Within-
human protein domain homologues offer the unique opportunity to answer this 
question. We compared the consistency of population-based genetic variation with 
evolutionary conservation across homologous domain positions by investigating 
81 Pfam domains that have at least 50 homologous instances in our set of human 
protein-coding genes, twice of what we need to ensure high-quality alignments 
(Methods). In total, for 6,536 positions of these 81 domains we measured relative 
entropies based on population and evolutionary variation in 14,059 human 
domain instances. We observe a high degree of correlation between these two 
groups (Pearson = 0.97, p-value < 1e-308; Methods; Figure 2a). We validated this 
result further by splitting the population–based entropies evenly into two separate 
groups, each consisting of 25 or more homologous instances. This way we can 
test for any noise in the computation of within-human conservation. Again, the 
relative entropies results in an almost perfect correlation (Pearson = 0.96, p-value 
< 1e-308; Figure 2b). These results show that variation in the human population 
measured across homologous protein domains faithfully mimics evolutionary 
conservation, thereby providing support for our proposed approach to aggregate 
genetic variation across domain homologues. 
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Figure 2. Evolutionary conservation and within-human conservation in Pfam domains 
For 81 domains that have 50 or more homologues within the human genome we computed the 
relative entropy to measure the conservation of amino acid residues per position in these domains 
for both evolutionary conservation based on Pfam and within-human conservation based on 
ExAC (Methods). In both plots the x and y-axis represent the relative entropy for a single position 
in a domain that ranges from 0.0 to 1.0; conserved to variable. A. On the y-axis evolutionary 
conservation is represented by the relative entropy per position based on Pfam. The x-axis shows 
variability measured solely in the human genome, based on relative entropy computed from 
ExAC. These two measurements show almost perfect correlation. (Pearson correlation coefficient 
= Pearson = 0.97, p-value < 1e-308). B. A validation of the results presented in A where we split the 
relative entropy measured solely in the human genome in two, hereby comparing the conservation 
solely between human protein domains. Again we observe an almost perfect correlation (Pearson 
correlation coefficient = 0.96, p-value < 1e-308).
To establish whether population variation adds additional information for variant 
interpretation compared to evolutionary conservation we assessed how disease-
causing and population-based missense variants are distributed with respect 
to evolutionary conservation. We expected to find that positions containing 
disease-causing variants are conserved in general, whereas positions with genetic 
missense variants common in the human population are expected to be variable. 
Therefore we investigated 17,195 positions in 1,079 Pfam domains with 31,732 
disease-causing missense variants from HGMD. Contrary to what we expected, 
more than 54% of the positions with a disease-causing missense variant were 
found to be evolutionary variable with a relative entropy of 0.5 or higher (Figure 
3a). The local maxima, observed between 0.0 and 0.1 relative entropy in Figure 
3a, was expected to degrade gradually for higher levels of entropy. As this is a 
measurement on protein domains, we hypothesize that this local maxima is 
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caused by mutations that affect active site residues. In line with our expectations, 
when we performed the same analysis for positions with missense variants that 
have >0.1% allele frequency in ExAC, we found that 77% of these positions was 
highly variable (Figure 3b). These results highlight that evolutionary conservation 
is not the perfect indicator for pathogenic mutations, and that population-based 
genetic tolerance scores may function as a complementary approach in variant 
interpretation.
Figure 3. Number of missense variants per position in a meta-domain in perspective of 
conservation
Plotted here is the binned distribution of positions that contain one or more missense variant of 
interest with respect to the evolutionary conservation of the position where these variants occur. 
The x-axes are denoted by “Relative entropy (Pfam)” and the y-axes are marked as the overall 
percentage of these positions. The figure shows that disease-causing missense variants also affect 
very variable sites. A. 17,195 different positions spanning 1,079 Pfam domains. On these positions 
31,732 disease-causing missense variants from HGMD were found in 22,651 domain occurrences 
in the human genome. Of these positions, 54% have relative entropy 0.5 or higher. B. 13,571 
different positions spanning 1,965 Pfam domains. On these positions 17,258 missense variants 
with an allele frequency above 0.1% in ExAC were found in 27,767 domain occurrences. 77% of 
these positions have relative entropy 0.5 or higher.
Creation of meta-domains by aggregating genetic variation over 
domain homologues
Based on our results that genetic variation is consistent across human protein 
domain homologues, and that population-based genetic variation correlates 
faithfully with evolutionary conservation, we hypothesized that genetic variation 
can be aggregated across homologous domains to provide a more detailed 
map of genetic variation. Hence, we projected disease-causing and population-
based missense variation found in human protein domains onto Pfam domain 
consensus positions giving rise to a “meta-domain” (Methods; Figure 4). In total 
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we successfully projected 20,404 population-based missense variants with >0.1 
% allele frequency from ExAC, 35,069 disease-causing missense mutations from 
HGMD and 8,569 pathogenic missense mutations from ClinVar (Supp. Data S5; 
Methods). We tested whether there was any overlap between the pathogenic and 
population-based missense variants on aligned positions by comparing HGMD 
DM with ExAC and found a negative correlation (Pearson = -0.51, p-value < 1e-308; 
Supp. Figure S1) indicating that disease-causing missense variants at aggregated 
domain positions often are paired with the absence high-frequency population 
missense variants and vice versa. This suggests that the information annotated to 
the meta-domains may be used to enhance variant interpretation.
To further confirm that aggregation of variants to Pfam domain consensus 
positions is meaningful, we perform two separate analyses. We first performed 
Monte Carlo experiments to test whether missense variants re-occur at the 
same position in domain homologues more often than could be expected by 
chance. We find that high-frequency population missense variants in 68% of 
the meta-domains re-occur at the majority of the aligned positions, and that 
this is significantly different from what may be expected by chance (Bonferroni 
corrected p<0.05 Welch’s t-test; Supp. Data S6 and S7; Methods). Similarly we 
find that HGMD DM and ClinVar Pathogenic missense variants, in 65% and 62% of 
the meta-domains respectively, re-occur at the majority of the aligned positions 
(Bonferroni corrected p<0.05 Welch’s t-test; Supp. Data S6 and S7). This analysis 
shows that the re-occurrence of missense variants found at aligned positions over 
all domain homologues follows a non-random pattern.
In our second analysis, again we perform Monte Carlo experiments and compute 
for each meta-domain our NCMVS metric to quantify how many missense variants, 
which re-occur at the same position, are also of identical change in amino acid 
(Methods). This way we find that high-frequency population missense variants 
in 21% of the meta-domains have significantly more variants of identical change 
at aligned positions across homologues as compared to what may be expected 
by chance. The pathogenic missense variants from HGMD DM and ClinVar 
Pathogenic datasets show a similar signal, with 23% and 18% respectively, of the 
meta-domains having an enriched NCMVS (Bonferroni correction p<0.05 Welch’s 
t-test; Supp. Data S7; Methods). This second analysis shows that the change in 
amino acid of missense variants found over all domain homologues is for a large 
set of domains more often identical than what may be expected by chance.
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Figure 4.Meta-domain construction in a schematic representation.
Genetic information is aggregated into a meta-domain based on domain homology. A. In this 
specific example there are three human proteins (indicated by the grey bars) with four domains 
that are found to have the same Pfam domain identifier and therefore belong to the same 
homologous domain group (indicated by A, B, C, and D). Red vertical lines in these domains 
indicate missense variants. There are other domains found in these proteins, but these are not 
further used in this specific example. B. The homologous domains together with their respective 
missense variants are extracted from the proteins and are aligned according to the Pfam domain. 
Based on the alignment the missense variants are then aggregated into a meta-domain. Some of 
these missense variants were aligned to the same position, in the meta-domain this is expressed 
with a higher blue column.
The results of these two analyses find that missense variation in domains follow a 
non-random pattern. Such a non-random pattern in pathogenic variants suggests 
that specific positions in domains are more likely to have a pathogenic effect via 
missense variants as compared to other positions. Conversely, finding a non-
random pattern for re-occurring high-frequency population missense variants 
provides insight into positions that are genetically tolerant. These findings support 
our hypothesis that variant information can be aggregated across homologous 




Investigating a meta-domain in detail
To illustrate how these meta-domains can straightforwardly be used to improve 
variant interpretation we investigated one meta-domain in detail; the “EGF-like 
domain” (PF00008). This domain has 244 homologous occurrences in 60 different 
human genes (Figure 5). The “EGF-like domain” has the second highest NCMVS in 
the context of HGMD DM missense variants, and the 13th highest based on high-
frequency population variants (Supp. Data S7). This suggests that the majority of 
variants often re-occur at aligned positions across the 244 homologues as identical 
changes in amino acids. Based on what is known from EGF-like domains, any 
changes to the conserved cysteines will cause loss of a stabilizing disulphide bond 
that are necessary for the structure of the domain.45 As expected, we find that the 
highly conserved cysteines are indeed enriched for disease-causing variants across 
the 244 homologues. Furthermore, all of the conserved cysteines are depleted 
for population-based missense variants, with the exception of consensus position 
six, confirming the importance of these residues. For consensus position six we 
observe that population variation is present in only one homologue. This specific 
variant in NOTCH4 (p.Cys815Gly, rs150079294) has an allele frequency 0.1632% 
in ExAC. dbSNP suggests that this variant is benign based on a single study75,76 
whereas our results further support the notion that this variant is problematic for 
this domain because of almost complete absence of common variation across the 
homologues. Even more interesting are the positions that are not evolutionary 
conserved (>0.6 relative entropy), but nevertheless depleted of population-based 
missense variation. In this “EGF-like domain” example, we find one such position 
at 21. In support of our hypothesis, we find multiple disease-causing missense 
mutations in different homologous domains at this position. We find that these 
▶Figure 5. An example of the EGF-like domain, represented as a meta-domain. 
The “EGF-like domain” (PF00008) occurring in 60 different human genes found to be significantly 
enriched for identical disease-causing missense variants across 244 homologues. X-axis shows the 
amino acid positions of this domain. The green bars in the top panel indicate how many missense 
variants with >0.1% allele frequency from ExAC are found over the 244 homologous domains and. 
The black bars indicate the number of missense variants that are of identical chance in amino 
acid (i.e. having identical reference and alternate residues). The middle panel denotes the Pfam 
HMM sequence logo generated via the Skylign tool42 where the height of each stack of residues 
indicates the relative entropy for that position. The thin red vertical lines in the sequence logo 
denote regions prone to contain deletions and the orange lines are regions prone to insertions 
based on the Pfam HMM. In the bottom panel red bars indicate the number of a disease-causing 
variant found across the 244 homologous domains. Black bars again indicate identical mutations. 
A comparison with ClinVar was made as well, albeit the dataset is much sparser as compared to 
HGMD (Supp Figure S7).





disease-causing mutations have been previously linked to CADASIL (OMIM #125310, 
p.Tyr337Cys, p.Tyr1021Cys, p.Tyr1069Cys in NOTCH3 (Q9UM47). CADASIL is an 
adult-onset autosomal dominant hereditary stroke disorder.77 Other mutations 
aligned to this consensus position are p.Tyr690Asp in JAG1 (P78604) associated 
with Biliary atresia extrahepatic (OMIM %210500), a disorder in infants that is 
fatal within the first two years of life when untreated,78,79 and p.Arg628Cys in CRB2 
(Q5IJ48) associated with Nephrotic syndrome steroid resistant (OMIM #616220), a 
childhood onset renal disorder.80
These results illustrate how meta-domains can be straightforwardly used to 
improve the interpretation of genetic variants of unknown significance. We 
have made our mapping of genomic positions to meta-domain identifiers and 
consensus positions available for the wider genetic community to make use of in 
Supp. Data S8.
Discussion
Here we combined two distinct concepts into a novel method for variant 
interpretation. Firstly, we used the observation that mutations at aligned 
positions in homologous proteins commonly lead to the same or similar effects 
on those proteins’ structure and function. Secondly, large datasets of population 
scale exome data have made it possible to determine the degree of intolerance 
to genetic variation for individual genes in order to identify potential disease 
genes. We combined these two concepts by aggregating population variation 
across homologous protein domain positions and thereby achieving single base 
resolution for genetic intolerance. As genetic data accumulates in the coming years, 
our method will become more and more accurate in predictions of intolerance at 
the single base pair level (Supp. Figure S2 and S3). 
To quantify genetic tolerance in genes, protein domains and domain homologues 
(Figure 1) we made use of the dN/dS score rather than other well-established 
tolerance scores such as pLI,50 RVIS,8 and subRVIS.9 The dN/dS metric was originally 
intended for detecting selective evolutionary pressure in protein-coding regions 
and genomes,81–83 and has previously been used by us and others to measure 
genetic tolerance and predict disease genes.10,59,84 Our choice for this score was 
motivated by the fact that the mentioned tolerance scores typically capture a 
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more general notion of tolerance to genetic variation and are not designed to 
measure tolerance for any specific genic region of interest.
Contrary to our expectations we found that 54% of disease-causing missense 
variants are evolutionary variable. There are some explanations why we find 
this result: Firstly, we did not take into account whether disease-causing variants 
asserted their effect in a dominant or a recessive fashion. We know that mutations 
in dominant disease genes are in general more conserved than mutations in 
recessive genes. Secondly, we know that not all disease-causing variants have the 
same severity in terms of fitness. For example, mutations causing infertility will be 
much more selected against than mutations causing genetic deafness. Thirdly, a 
large percentage of HGMD DM variants used to be present in recent population 
databases and may therefore be incorrect.85 Although in the version we used, 
this number was significantly reduced, some may still be present.86,87 Finally, our 
comparison does not account for unobserved (potentially lethal) variants, as many 
of these variants are likely to have never been observed, nor ever will be. 
In our meta-domains, we tested whether high-frequency missense variants with an 
allele frequency > 0.1% in ExAC are repeatedly enriched or depleted on Pfam domain 
consensus positions. This strict cut-off of 0.1% may cause us to miss variants with 
allele frequencies smaller than 0.1% at corresponding positions in homologues. 
We choose this cut-off in order to exclude the possibility of artefacts in the ExAC 
database, and for increasing the likelihood that variation is truly benign. Setting a 
stricter threshold such as 0.5% decreases the number of ExAC missense variants 
in meta-domains by 56%. Allowing for a less stringent cut-off will add a substantial 
amount of genetic variation to our model that would improve our sensitivity, but 
likely at the cost of specificity (Supp. Figure S4, Supp, Data S9). We expect there 
is still much to be gained from these ‘rare’ variants found in population cohorts. 
Furthermore we note that by aggregating genetic variation, the specific context 
such as haplotype information or interactions with other proteins, may be lost. 
An aggregation may only encapsulate general biological or molecular functions 
attributed to the domain. Nonetheless, we believe these meta-domains can be 
used to better interpret variants of unknown significance simply based on our pre-
calculated meta-domains (Supp. Data S5 and S8), but also by incorporating these 




All supplementary information can be found online with the published article at
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The growing availability of human genetic variation has given rise to novel 
methods of measuring genetic tolerance that better interpret variants of unknown 
significance. We recently developed a concept based on protein domain homology 
in the human genome to improve variant interpretation. For this purpose, we 
mapped population variation from the Exome Aggregation Consortium (ExAC) and 
pathogenic mutations from the Human Gene Mutation Database (HGMD) onto 
Pfam protein domains. The aggregation of these variation data across homologous 
domains into meta-domains allowed us to generate amino acid resolution of 
genetic intolerance profiles for human protein domains. 
Here, we developed MetaDome, a fast and easy-to-use web server that visualizes 
meta-domain information and gene-wide profiles of genetic tolerance. We updated 
the underlying data of MetaDome to contain information from 56,319 human 
transcripts, 71,419 protein domains, 12,164,292 genetic variants from gnomAD, 
and 34,076 pathogenic mutations from ClinVar. MetaDome allows researchers 
to easily investigate their variants of interest for the presence or absence of 
variation at corresponding positions within homologous domains. We illustrate 
the added value of MetaDome by an example that highlights how it may help in 
the interpretation of variants of unknown significance. The MetaDome web server 
is freely accessible at https://stuart.radboudumc.nl/metadome.
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The continuous accumulation of human genomic data has spurred the development 
of new methods to interpret genetic variants. There are many freely available web 
servers and services that facilitate the use of these data by non-bioinformaticians. 
For example, the ESP Exome Variant Server58,88 and the Genome Aggregation 
Database (gnomAD) browser50,89 help locate variants that occur frequently in the 
general population. These services are used for the interpretation of unknown 
variants based on the assumption that variants occurring frequently in the general 
population are unlikely to be relevant for patients with Mendelian disorders.90 
There are also methods that derive information from these large human genetic 
databases. For example genetic intolerance, which is commonly used to interpret 
variants of unknown significance by assessing whether variants stand out because 
they occur in regions that are genetically invariable in the general population.9,10 
Examples of such methods are RVIS8 and subRVIS.9 The strongest evidence for the 
pathogenicity of a genomic variant comes from the presence of that variant in 
any of the clinically relevant genetic variant databases such as the Human Gene 
Mutation Database (HGMD)91 or the public archive of clinically relevant variants 
(ClinVar).54 These databases are gradually growing in the amount of validated 
pathogenic information. 
Another way to provide evidence for the pathogenicity of a genomic variant is to 
observe the effect of that variant in homologous proteins across different species. 
Mutations at corresponding locations in homologous proteins are found to result 
in similar effects on protein stability40 and can facilitate variant interpretation 
between disease genes and their paralogues.92 Finding homologous proteins is one 
the key applications of BLAST.38 Transferring information between homologous 
proteins is one of the oldest concepts in bioinformatics, and can be achieved by 
performing a multiple sequence alignment (MSA) and locating equivalent positions 
between the protein sequences. We have previously used this concept and showed 
that it also holds for homologous Pfam protein domain relationships within the 
human genome. We found that ~71-72% of all disease-causing missense variants 
from HGMD and ClinVar occur in regions translating to a Pfam protein domain and 
observed that pathogenic missense variants at equivalent domain positions are 
often paired with the absence of population-based variation and vice versa.93 By 
aggregating variant information over homologous protein domains, the resolution 
of genetic tolerance per position is increased to the number of aligned positions. 
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Similarly, the annotation of pathogenic variants found at equivalent domain 
positions also assists the interpretation of variants of unknown significance. This 
use of variant information from homologous protein domains was dubbed ‘meta-
domains’. We realized that this type of information could be of great benefit to the 
genetics community and therefore developed ‘MetaDome’.
MetaDome is a freely available web server that uses our concept of meta-domains 
to optimally use the information from population-based and pathogenic variation 
datasets without the need of a bioinformatics intermediate. MetaDome is easy to 
use and utilizes the latest population datasets by incorporating the gnomAD and 
ClinVar datasets.
Methods
Software architecture of MetaDome
MetaDome is developed in Python v3.5.194 and makes use of the Flask framework 
v0.12.495 for the web server part which communicates between the front-end, the 
back-end, and the database. The software architecture (Supp. Figure S5) follows 
the Domain-driven design paradigm.96 The entities in the domain part of this 
software architecture are rich data representations that are based on the internal 
database (Creating the mapping database) and annotations from external 
resources. These entities are stored after their first creation and afterward directly 
used for data retrieval to make the lookup in MetaDome as efficient as possible. 
The code is open source and can be found at our GitHub repository: https://github.
com/cmbi/metadome. Detailed instructions on how to deploy the MetaDome web 
server can be found there too. 
To ensure MetaDome can be deployed to any environment and provide a high 
degree of modularity, we have containerized the application via Docker v17.12.1.97 
We use docker-compose v1.17.1 to ensure that different containerized aspects of 
the MetaDome server can work together. The following aspects are containerized 
to this purpose: 1.) The Flask application, 2.) a PostgreSQL v10 database wherein 
the mapping database is stored, 3.) a Celery v4.2.0 task queue management 
system to facilitate the larger tasks of the MetaDome web-based user requests, 4.) 
a Redis v4.0.11 for task result storage, and 5.) RabbitMQ v3.7 to mediate as a task 
broker between client and workers. For a full overview of the docker-compose 




The visualization medium of the MetaDome web server is a fully interactive and 
responsive HTML web page. This page is generated by the Flask framework and 
the navigation aesthetics are made using the CSS framework Bulma v0.7.1.98 The 
visualizations of the various landscapes and the schematic protein are created 
with JavaScript, JQuery v3.3.1, and the D3 Framework v4.13.0.99 As the visualization 
by the D3 Framework is highly dependent on the user’s cpu power, so are the 
visualizations of MetaDome.
Datasets of population and disease-causing genetic variation
MetaDome makes use of single nucleotide variants (SNVs) from population and 
clinically relevant genetic variation databases. Population variation was obtained 
from the gnomAD r2.0.2 VCF file by selecting all synonymous, nonsense, and 
missense variants that meet the PASS filter criteria. Variants meeting the PASS 
criteria are considered to be true variants.50 The variants in the VCF file from 
ClinVar release 2018 05 03 with disease-causing (Pathogenic) status are used as 
the disease-causing SNVs in MetaDome.
Creating the mapping database
MetaDome stores a complete mapping between genomic, protein positions, and 
all domain annotations (Supp. Figure S7) in a PostgreSQL relational database.100 
This mapping is auto-generated and stored in the PostgreSQL database by the 
MetaDome web server upon the first run. The genomic positions consist of each 
chromosomal position in the protein-coding transcripts of the GENCODE release 
19 GRCh37.p13 Basic set.63 The protein positions correspond to protein sequence 
positions in the UniProtKB/Swiss-Prot Release 2016_09 databank entries for 
the human species.64 These mappings are created with Protein-Protein BLAST 
v2.2.31+62 for each protein-coding translation in the GENCODE Basic set to human 
canonical and isoform Swiss-Prot protein sequences. We exclude sequences that 
do not start with a start codon (i.e. ATG encoding for methionine), or end with 
a stop codon. We checked if the cDNA sequence of the transcripts match the 
GENCODE translation via Biopython’s translate function,101 if they are not identical 
then these are excluded too. The global information on the transcript (e.g. 
identifiers, sequence length) is registered in the database in the table ‘genes’ and, 
for each Swiss-Prot entry with an identical sequence match, the global information 




Next, for each identical match between translation and Swiss-Prot sequence 
a ClustalW2 v2.139 alignment is made between these two sequences. Each 
nucleotide’s genomic position is mapped to the protein position and stored in the 
‘mappings’ table. Each entry in mapping represents a single nucleotide of a codon 
and is linked to the corresponding entry in the ‘genes’ and ‘proteins’ table (i.e. the 
corresponding GENCODE translation, transcription and Swiss-Prot sequence). 
Each Swiss-Prot sequence in the database is annotated via InterProScan v5.20-
59.065 for Pfam-A v30.0 protein domains41 and the results are stored in the 
‘interpro_domains’ table. After the construction of the database is finished, all 
meta-domain alignments can be constructed.
Composing a meta-domain
Meta-domains consist of homologous Pfam protein domain instances that are 
annotated using InterproScan. Meta-domains consist of domains that have at 
least two homologues within the human genome. MSAs are made using a three 
step process. 1.) Retrieve all sequences for the domain instances, 2.) Retrieve the 
Pfam HMM corresponding to the Pfam identifier annotated by InterproScan, and 
3.) Use HMMER 3.1b267 to align the sequences from the first step. The resulting 
Stockholm format MSA files can be inspected with alignment visualization software 
like Jalview.102 In this Stockholm formatted file, all columns that correspond to the 
domain consensus represent the same homologous positions.
These Stockholm files are retrieved by the MetaDome web server when a user 
request meta-domain information for a position of their interest. Upon retrieval 
of this Stockholm file, the mapping database is used to obtain the corresponding 
genomic positions for each residue. These genomic positions are subsequently 
used to retrieve corresponding gnomAD or ClinVar variation.
Computing genetic tolerance and generating a tolerance landscape
The non-synonymous over synonymous ratio, or dN/dS score, is used to quantify 
genetic tolerance. This score is based on the observed (obs) missense and 
synonymous variation in gnomAD (missenseobs and synonymousobs). This score is 
corrected for the sequence composition by taking into account the background 
(bg) of possible missense and synonymous variants based on the codon table 




The tolerance landscape computes this ratio as a sliding window of size 21 (i.e. 
ten residues before and ten after the residue of interest) over the entirety of the 
gene’s protein, similar to the Missense Tolerance Ratio (MTR) presented by.103 The 
edges (e.g. start and end) are therefore a bit noisy as they are not the result of 
averaging over a full length window.
Results
Accessibility
The MetaDome web server is freely accessible at https://stuart.radboudumc.nl/
metadome. MetaDome features a user-friendly web interface and features a fully 
interactive tour to get familiar with all parts of the analysis and visualizations. 
All source code and detailed configuration instructions are available in our GitHub 
repository: https://github.com/cmbi/metadome.
The underlying database: a mapping between genes and proteins
The MetaDome web server queries genomic datasets in order to annotate 
positions in a protein or a protein domain. Therefore, the server needs access to 
genomic positional information as well as protein sequence and protein domain 
information. The database maps GENCODE gene translations to entries in the 
UniProtKB/Swiss-Prot databank in a per-position manner and corresponding 
protein domains or genomic variation. With respect to our criteria to map gene 
translations to proteins (Methods; creating the mapping database), 42,116 of 
the 56,319 full-length protein-coding GENCODE Basic transcripts for 19,728 human 
genes are linked to 33,492 of the 42,130 Swiss-Prot human canonical or isoform 
sequences. Of the total 591,556 canonical and isoform sequences present in 
Swiss-Prot, 42,130 result from the Human species. The resulting mappings contain 
32,595,355 unique genomic positions that are linked to 19,226,961 residues in 
Swiss-Prot protein sequences.
71,419 Pfam domains are linked to 30,406 of the Swiss-Prot sequences in our 
database. Of these Pfam domain instances, 5,948 are from a unique Pfam domain 
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family and 3,334 of these families have two or more homologues and are therefore 
suitable for meta-domain construction. Thus, by incorporating every protein-
coding transcript, instead of only the longest ones, we increase the previously 
2,75093 meta-domains to 3,334. These meta-domains, on average, consist of 
16 human protein domain homologues with a protein sequence length of 158 
residues. Table 1 summarizes the counting statistics for sequences, domains, etc.
Database What # of entries
GENCODE Protein-coding genes 20,345
MetaDome Protein-coding genes 19,728
GENCODE Protein-coding transcripts 57,005
MetaDome Protein-coding transcripts 56,319
Swiss-Prot Canonical and isoform protein sequences 591,556
Swiss-Prot Human canonical and isoform protein sequences 42,130
MetaDome Gene translations identically mapped to a canonical 
or isoform protein sequence
42,116
MetaDome Canonical and isoform protein sequences 33,492
MetaDome Pfam protein domain regions 71,419
MetaDome Unique Pfam protein domain families 5,948
MetaDome Unique Pfam protein domain families with two or 
more within-human occurrences
3,334
MetaDome Chromosome to protein position mappings 70,261,143
MetaDome Unique chromosome positions 32,595,355
MetaDome Unique residues (as part of a protein) 19,226,961
MetaDome Unique protein sequences with at least one Pfam 
domain annotated
30,406
Table 1. Statistics on the number of entries present in GENCODE, Swiss-Prot, and our mapping 
database.
How to use the MetaDome web server
At the welcome page users are offered the option to start an interactive tour or 
start with the analysis. The navigation bar at the top is available throughout all 
web pages in MetaDome and allow for further navigation to the ‘About’, ‘Method’, 
‘Contact’ page (Supp. Figure S1). The user can fill in a gene symbol in the ‘gene 
of interest’ field and is aided by an auto-completion to help you find your gene 
of interest more easily (Supp. Figure S2). Clicking the ‘Get transcripts’ fills all 




are mapped to a Swiss-Prot protein can be used in the analysis, the others are 
displayed in grey (Supp. Figure S3).
Clicking the ‘Start Analysis’ button starts an extensive query to the back-end of the 
web server for the selected transcript. Firstly, all the mappings are retrieved for 
the transcript of interest. Secondly, the entire transcript is annotated with ClinVar 
and gnomAD single nucleotide variants (SNVs) and Pfam domains. Thirdly, if there 
are any Pfam domains suitable for meta-domain relations then all mappings for 
those regions are gathered and annotated with ClinVar and gnomAD variation 
(methods; Composing a meta-domain).
The web-page provided to the user as a result of the ‘Analyse Protein’ can best be 
explained using an example. Therefore, we have generated this result for gene 
CDK13 for transcript ‘ENST00000181839.4‘ (Figure 1). The result page features four 
main components that we will describe from top to bottom. Located at the top is 
the graph control field. Directly below the graph control is the landscape view of 
the protein. Below the landscape view, a schematic and interactive representation 
of the protein and an additional representation of the protein which controls 
the zooming option. Lastly, at the bottom of the page there is the list of selected 
positions. All of these components are interactive and the various functionalities 
are described in Table 2.
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Figure 1. MetaDome web server result for the gene CDK13
The result provided by the MetaDome web server for the analysis of gene CDK13 with transcript 
ENST00000181839.4, as provided in 1.). In 2.), there is additional information that the translation 
of this transcript corresponds to Swiss-Prot protein Q14004. Here also various alternative 
visualizations can be selected. The visualization starts by default in the ‘meta-domain landscape’, 
a mode selectable in the graph control in 2.). The landscapes are visualized in 3.), and in the 
meta-domain landscape the domain regions are annotated with missense variation counts found 
in homologous domains as bar plots. The schematic protein representation, located at 4.), is 
per-position selectable, and the domains are presented as purple blocks. Selected positions are 
highlighted in green. The ‘Zoom-in’ section at 5.) features a selectable greyed-out copy of schematic 
protein representation that can zoom-in on any part of the protein. Any selected positions are 
in the list of selected positions in 6.). Here more information can be obtained by clicking on one 






Gene and transcript input 
field 
(Figure 1.1)
• Input of gene of interest
• Retrieving transcripts for gene of interest
• Selecting a transcript
• Starting the analysis for selected transcript
Graph control field 
(Figure 1.2)
• Toggling between different landscape representations
• Reset the zoom on the landscape
• Reset the web page
• Toggle ClinVar variants to be displayed in the schematic 
protein
• Download the visual representation
Landscape view 
(Figure 1.3)
• Displays the meta-domain landscape
• Displays the tolerance landscape
Schematic protein 
(Figure 1.4)
• Displays a schematic representation of the gene’s protein 
with Pfam protein domains annotated
• Hovering over a position displays positional information
• Clicking on a position highlights the position and adds the 
position to the list of ‘Selected Positions’




• Displays any positions selected in the schematic protein
• Displays per selected position: if that position is part of 
a Pfam protein domain, any known gnomAD or ClinVar 
variants present at this position, and any variants that are 
homologously related to this position
• Provides more detailed information as a pop-up when 
clicking on one of the positions in this list. 
Table 2. Descriptions of the various functionalities on the MetaDome result page.
Another way to use population-based variation in the context of the entire 
protein is via the tolerance landscape representation in MetaDome that can be 
selected in the graph control component (Figure 1.2). The tolerance landscape 
depicts a missense over synonymous ratio (also known as Ka/Ks or dN/dS) over 
a sliding window of 21 residues ovr the entirety of the protein of interest (e.g. 
calculated for ten residues left and right of each residue) based on the gnomAD 
dataset (methods; Computing genetic tolerance and generating a tolerance 
landscape; Figure 2A). Previously, the dN/dS metric has been used by others and 
us to measure genetic tolerance and predict disease genes,59,84,104 and it is suitable 
for measuring tolerance in regions within genes.10
An example of using the MetaDome web server for variant 
interpretation
The MetaDome analysis result for CDK13 (Figure 1) is the longest protein coding 
transcript for CDK13 with a protein sequence length of 1,512 amino acids. In the 
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resulting schematic protein representation we can observe the Pkinase Pfam 
protein domain (PF00069) between positions 707 and 998 as the only protein 
domain in this gene (Figure 2B). The Pkinase domain is highly prevalent throughout 
the human genome with as many as 779 homologous occurrences in human 
proteins, of which 353 are unique genomic regions. It is the 8th most occurring 
domain in our mapping database. The meta-domain landscape is the default view 
mode and shows any missense variation found in homologous domain occurrences 
throughout the human genome. Population-based (gnomAD) missense variation 
is displayed in green and pathogenic (ClinVar) missense variation is annotated in 
red bars, with the height of the bars depicting the number of variants found at 
each position (Figure 2B).
At the ‘Display ClinVar variants’ the user is provided two options; to highlight all 
known pathogenic information known for the current protein and/or highlight any 
ClinVar variants that are present at homologous positions (Figure 2A). All ClinVar 
variants highlighted are displayed in red. In total six known disease-causing SNVs 
are present in the CDK13 gene itself according to ClinVar, and these all fall within 
the Pkinase protein domain. All of these are missense variants. If we add variants
▶ Figure 2. Examples of a MetaDome analysis for the gene CDK13
A.) The tolerance landscape depicts a missense over synonymous ratio calculated as a sliding 
window over the entirety of the protein (methods; Computing genetic tolerance and generating 
a tolerance landscape). The missense and synonymous variation are annotated from the 
gnomAD dataset and the landscape provides some indication of regions that are intolerant to 
missense variation. In this CDK13 tolerance landscape the Pkinase Pfam protein domain (PF00069) 
in purple can be clearly seen as intolerant if compared to other parts in this protein. The red bars 
in the schematic protein representation correspond to pathogenic ClinVar variants found in this 
gene and in homologous protein domains. All of these variants are contained in the intolerant 
region of the landscape.
B.) A zoom-in on the meta-domain landscape for CDK13. The Pkinase Pfam protein domain 
(PF00069) is located between protein positions 707 and 998 and annotated as a purple box in the 
schematic protein representation. The meta-domain landscape displays a deep annotation of the 
protein domain: the green (gnomAD) and red (ClinVar) bars correspond to the number of missense 
variants found at aligned homologous positions. Unaligned positions are annotated as black bars. 
All of this information is displayed upon hovering over these various elements.
C.) The positional information provides a detailed overview of a position from the ‘Selected 
Positions’ list, especially if that position is aligned to domain homologues. Here, for position 
p.Gly714 we can observe in 1.) the positional details for this specific protein position. In 2.) is any 
known pathogenic information for this position. We can observe here that for this position there 
are two known pathogenic missense variants. In 3.) meta-domain information is displayed and we 
can observe that p.Gly714 is aligned to consensus position 10 in the Pkinase Pfam protein domain 
and related to 329 other codons. This consensus position has an alignment coverage of 93.5% for 
the meta-domain MSA. There are also four pathogenic variants found in ClinVar on corresponding 
homologous positions as can be seen in 4.) and in 5.) there is an overview of all corresponding 






found in homologous domains there are 64 positions with one or more reported 
pathogenic variants (Supp. Data S1). Four of these positions overlap with the 
positions on which ClinVar variants were found in the gene itself and on position 
p.883 (Supp. Figure S4) we can observe a peak of eight missense variants 
annotated from other protein domains.
MetaDome helps to look in more detail to a position of interest. If we do this for 
protein position 714 (Figure 2C) in CDK13 we find that it corresponds to consensus 
position 10 in the Pkinase domain (PF00069). At this position in CDK13 there are 
two variants reported in ClinVar: p.Gly714Arg (ClinVar ID: 375738) submitted by,105 
and p.Gly714Asp (ClinVar ID: 449224) submitted by GeneDX. The first is reported 
as a de novo variant and is associated to Congenital Heart Defects, Dysmorphic 
Facial Features, and Intellectual Developmental Disorder. For the second there 
is no associated phenotype provided. As MetaDome annotates variants reported 
at homologous positions, we can find even more information for this particular 
position. At the homologues aligned to this position we find a variant of identical 
change in PRKD1: p.Gly600Arg (ClinVar ID: 375740) reported as pathogenic and 
de novo in the same study.105 It is also associated to Congenital Heart Defects 
as well as associated to Ectodermal Dysplasia. There are three more reported 
pathogenic variants aligned to this position: MAK:p.Gly13Ser (ClinVar ID: 29783) 
associated to Retinitis Pigmentosa 62,106 PRKCG:p.Gly360Ser (ClinVar ID: 42129) 
associated to Spinocerebellar Ataxia Type14,107 and CIT:p.Gly106Val (ClinVar ID: 
254134) associated to Microcephaly 17, primary, autosomal recessive.106 These 
homologously related pathogenic variants and the severity of the associated 
phenotypes contributes to the evidence that this particular residue may be 
important at this position. Further evidence can be found from the fact that in 
human homologue domains this residue is extremely conserved. There are 330 
unique genomic regions encoding for a codon aligned to this position (Supp. Data 
S2). Only in the gene PIK3R4 (ENST00000356763.3) does this codon encode for 
another residue than Glycine, namely a Threonine at position p.Thr35.
In the same way that we explored pathogenic ClinVar variation we can also 
explore the variation reported in gnomAD. In CDK13 at protein position 714 there 
is no reported variant in gnomAD, but there are homologously related variations. 
There are 65 missense variants with average allele frequency of 1.24E-05 and 
76 synonymous with average allele frequency 8.71E-03 and there is no reported 




When we inspect the tolerance landscape for CDK13 (Figure 2A) we can see that 
all of the ClinVar variants (either annotated in CDK13 or related via homologues) 
fall within the Pkinase Pfam protein domain (PF00069). In addition, the protein 
domain can clearly be seen as more intolerant to missense variation as compared 
to other parts of this protein, thereby supporting the ClinVar variants likely 
pathogenic role.
Conclusion
The MetaDome web server combines resources and information from different 
fields of expertise (e.g. genomics and proteomics) in order to increase the power 
in analysing population and pathogenic variation by transposing this variation 
to homologous protein domains. Such a transfer of information is achieved by 
a per-position mapping between the GENCODE and Swiss-Prot databases. 79.4% 
of the Human Swiss-Prot protein sequences are of identical match to one or 
more of 42,116 GENCODE transcripts. This means that 25.7% of the GENCODE 
transcriptions differ in mRNA but translate to the same Swiss-Prot protein 
sequence. GENCODE previously reported that this is due to alternative splicing, of 
which a substantial proportion only affect untranslated regions (UTRs) and thus 
have no impact on the protein-coding part of the gene.108
MetaDome is especially informative if a variant of interest falls within a protein 
domain that has homologues. This is highly likely as 43.6% of the positions in 
the MetaDome mapping database are part of a homologous protein domain. 
Pathogenic missense variation is also highly likely to fall within a protein domain 
as we previously observed for 71% of HGMD and 72% of ClinVar pathogenic 
missense variants.93 By aggregating variation over protein domain homologues via 
MetaDome, the resolution of genetic tolerance at a single amino-acid is increased. 
Furthermore, we can obtain variation that could disrupt the functionality of a 
protein domain, as annotated throughout the entire human genome, which may 
potentially be disease-causing. It should be noted, that by aggregating genetic 
variation in this way the specific context such as haplotype information or 
interactions with other proteins may be lost. Aggregation via meta-domains only 
encapsulates general biological or molecular functions attributed to the domain. 
Nonetheless, we believe MetaDome can be used to better interpret variants of 
unknown significance through the use of meta-domains and tolerance landscapes 
as we have shown in our example.
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As more genetic data accumulates in the years to come, MetaDome will become 
more and more accurate in predictions of intolerance at the base-pair level and the 
meta-domain landscapes will become even more populated with variation found 
in homologue protein domains. We can imagine many other ways of integrating 
this type of information to be helpful for variant interpretation. Future directions 
for the MetaDome web server could lead to machine learning empowered variant 
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Haploinsufficiency (HI) is the best characterized mechanism through which 
dominant mutations exert their effect and cause disease. Non-haploinsufficiency 
(NHI) mechanisms, such as gain-of-function and dominant-negative mechanisms, 
are often characterized by the spatial clustering of mutations, thereby 
affecting only particular regions or base pairs of a gene. Variants leading to 
haploinsufficency might occasionally cluster as well, for example in critical 
domains, but such clustering is on the whole less pronounced with mutations 
often spread throughout the gene. Here we exploit this property and develop a 
method to specifically identify genes with significant spatial clustering patterns of 
de novo mutations in large cohorts. We apply our method to a dataset of 4,061 de 
novo missense mutations from published exome studies of trios with intellectual 
disability and developmental disorders (ID/DD) and successfully identify 15 genes 
with clustering mutations, including 12 genes for which mutations are known 
to cause neurodevelopmental disorders. For 11 out of these 12, NHI mutation 
mechanisms have been reported. Additionally, we identify three candidate ID/DD-
associated genes of which two have an established role in neuronal processes. We 
further observe a higher intolerance to normal genetic variation of the identified 
genes compared to known genes for which mutations lead to HI. Finally, 3D 
modeling of these mutations on their protein structures shows that 81% of the 
observed mutations are unlikely to affect the overall structural integrity and that 
they therefore most likely act through a mechanism other than HI.
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De novo mutations affecting protein-coding genes are a major cause of intellectual 
disability (ID) and other developmental disorders (DDs).59,109 Several whole exome 
sequencing (WES) studies have identified ID syndromes molecularly characterized 
by very specific spatial clustering of de novo missense mutations.110–113 Similarly, 
large-scale WES studies of individuals affected by ID/DD have recently leveraged this 
phenomenon as supporting evidence of the involvement of a gene in disease.70,114 
This spatial clustering of de novo mutations (DNMs) is typical for missense 
mutations in genes without clear, or limited numbers of, truncating mutations 
subsequently degraded by nonsense mediated mRNA decay, suggesting that these 
clustered mutations act through a different mechanism than haploinsufficiency 
(HI).115 Alternative pathophysiological mechanisms that might underlie (de novo) 
mutation clustering are gain-of-function or dominant-negative effects, resulting 
in the alteration or impairment of specific protein function.116,117 We note that 
while spatial clustering is commonly taken to indicate a mechanism different from 
loss-of-function,118 this is not an absolute rule, and a loss-of-function mechanism 
cannot be excluded without functional evidence.119 Here, we developed a method 
to identify genes with spatially clustered DNMs and applied this to DNMs identified 
in a large cohort of individuals with ID/DD.120
We downloaded all DNMs occurring in individuals with ID/DD from denovo-
db version 1.3120 identified through WES and whole genome sequencing which 
were then re-annotated with our in-house variant annotation pipeline. The de 
novo mutations included in the analysis were previously validated by a second 
independent method or showed a high validation rate for a subset of de novo 
mutations. In addition, we added 1,183 de novo variants identified in the exomes 
of an in-house ID cohort that was previously published.70 To further reduce the 
risk of including sequencing artifacts and/or genotyping errors, we excluded all de 
novo variants that were present more than once in the ExAC dataset (Table S1).50 
These efforts resulted in 6,495 protein coding DNMs, including 4,061 missense 
mutations, in 5,302 individuals with ID/DD (Table S2).
We set out to determine for any gene whether the observed de novo missense 
mutations cluster more than expected compared to random permutations. 
Hereto, we selected for each the longest representative transcript (i.e. part of 
the GENCODE basic set)63 and calculated the geometric mean distance  over 
all missense DNMs on cDNA.  was calculated by taking the mean distance 
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normalized for transcript length l over all (M) combinations of xi and xj of the 
missense DNMs (Equation 1.), where x represents the position for mutation i and 
j respectively. Statistical significance was determined by performing 1.00E+08 (or 
N) permutations and calculating for each permuted geometric mean distance ( ) 
how many times this resulted in the same or smaller geometric mean distance as 
observed (Equation 2.) Permutation p-values were corrected for multiple testing 
via Bonferroni procedure based on the 19,280 genes of the Agilent SureSelect v5 
exome enrichment kit. 
1.
2.
We first validated our method on a dataset of DNMs identified in 2,448 unaffected 
siblings and healthy control studies120–126 (Table S3). In this cohort, we failed to 
identify genes for which clustering of de novo missense mutations reached 
statistical significance (Table S4). However, application of our method to the 
dataset of 4,061 DNMs, containing 583 genes with more than one de novo missense 
mutation, revealed 15 genes with significant clustering70,114,127–129 (Table 1, Figure 
1, Figures S1-S15). In these genes, a total of 107 de novo missense mutations 
contributed to mutation clustering, ranging from three to 20 mutations per gene 
with an average distance ranging from 0 to 354 bp. To exclude a correlation 
between the extent of clustering and the total number of de novo missense 
mutations analyzed, we applied our method to a cohort of 6,154 de novo missense 
variants present in Denovo-db excluding the five studies incorporated in the ID/DD 
cohort, and found no such correlation (Figure S16). To examine whether this set 
of 15 genes is relevant in the context of ID/DD, we compared these genes to a list 
of 1,541 genes for which mutations are known to cause ID/DD (Table S5). This list 
of genes was a compilation of two manually curated lists of disease related genes 
including “confirmed” unique genes from DDG2P (n=1,098; see Web Resources) 
and 1,034 genes offered for diagnostic testing in individuals with ID/DD by our 
de novo missense mutations identifies candidate neuro-developmental disorder
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in-house diagnostic facility (see Web Resources). Among the 15 identified genes 
with mutation clustering, we find 12 genes for which mutations have previously 
been implicated in ID/DD, constituting a significant enrichment (p=3.09e-03; 
Fisher’s exact test; Tables S6 and S7), and confirming that our method is valid for 
its purpose.. The inclusion of exome data of two large DDD-studies in both the 
DDG2P gene list and the ID/DD cohort of this study could introduce a potential 
bias109,114. To exclude such bias we repeated this analysis while excluding the DDD 
specific genes identified in the two exome studies yielding a significant enrichment 
(p=3.68E-02; Table S7A-C).
Figure 1. Examples of Identified Genes with Clustering Mutations
Protein domains are annotated based on Pfam HMM search.41 cDNA locations of de novo missense 
mutations are depicted by blue pins. Genes shown here are as follows: SMAD4 (A), CDK13 (B), 
PACS2 (C). Figures visualizing the clustering of de novo missense mutations in the other 12 genes 
are provided in Figures S1–S15.
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Table 1. List of identified genes with clustering de novo missense mutations. Genes previously 
known to be involved in neurodevelopmental disorders are indicated in italics. P-values are based 
on a permutation test (N=1.00E+08). Adj. p-values are corrected by Bonferroni correction. The 
three identified genes with that have not yet been implicated in ID/DD are indicated by an ‘a’. 







ACTL6Ba ENST00000160382 3 0 5.70E-07 1.10E-02
ALG13 ENST00000394780 3 0 1.50E-07 2.89E-03
CDK13 ENST00000181839 12 273 <1.00E-08 <1.93E-04
COL4A3BP ENST00000380494 6 18 2.60E-07 5.01E-03
GABBR2a ENST00000259455 3 0 9.00E-08 1.74E-03
GRIN2B ENST00000609686 11 354 1.57E-06 3.03E-02
KCNH1 ENST00000271751 7 65 1.00E-07 1.93E-03
KCNQ2 ENST00000354587 20 301 5.00E-08 9.64E-04
KIF5C ENST00000435030 3 0 1.40E-07 2.70E-03
PACS1 ENST00000320580 9 0 <1.00E-08 <1.93E-04
PACS2a ENST00000458164 3 0 1.50E-07 2.89E-03
PCGF2 ENST00000360797 3 0 1.11E-06 2.14E-02
PPP2R1A ENST00000322088 4 5 4.60E-07 8.87E-03
PPP2R5D ENST00000485511 16 10 <1.00E-08 <1.93E-04
SMAD4 ENST00000398417 4 6 1.60E-07 3.08E-03
We also identified three genes with clustered de novo missense mutations that 
have not yet been implicated in ID/DD: ACTL6B (MIM:612458), GABBR2 (MIM:607340) 
and PACS2 (MIM:610423). None of these genes would have been identified based 
on enrichment for de novo mutations in this cohort (Table S8). Further systematic 
evaluation of gene function supports a role in (neuro)development for two of 
these genes (Table 2 and Table S9). ACTL6B, encoding Actin-like 6B (also known 
as BAF53B), is a pivotal co-factor for the SWI/SNF neuron-specific chromatin 
remodeling complex nBAF, which is required for neural development and 
dendritic outgrowth.130,131 Also, GABBR2, which is a component of the G-protein-
coupled GABA receptor, plays a critical role in the fine-tuning of inhibitory synaptic 
transmission,132–134 and other members of the GABA receptor family have already 
been conclusively linked to neurodevelopmental disorders.135,136 GABBR2 was very 
recently also reported by others to show significant de novo mutation clustering 
in a neurodevelopmental cohort.113
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Table 2. Gene function for candidate genes with clustered mutations. First column indicates 
the gene name, second column a summary of the known gene functions; third column indicates 
whether the gene has physical interactions with other proteins. (See Table S9 for extended 
information).
Summary of gene function Interactions
ACTL6B Belongs to the neuron-specific chroma-
tin remodeling complex (nBAF complex) 
and is required for postmitotic neural 
development and dendritic outgrowth. 
Complex formation with ACTB, 
ARID1A, SMARCA2, SMARCA4, 
SMARCE1, SMARCC1, SMARCC2, 
SMARCD2, SMARCB1
GABBR2 Postsynaptic GABAB Receptor Activity 
Regulates Excitatory Neuronal Architec-
ture and Spatial Memory.
Heterodimerization is required 
for the formation of a functional 
GABA-B receptor.
PACS2 Multifunctional sorting protein, contro-
ling endoplasmic reticulum-mitochond-
ria communication and Bid-mediated 
apoptosis.
 N/A
Our method might potentially identify clustering based on identical mutations 
in multiple individuals only as a result of issues in the underlying cohort. It 
could for instance be that the same individual was included in multiple studies 
and therefore occurs twice in the cohort. For 99 out of 107 de novo missense 
mutations (92.5%) occurring in the 15 genes with clustering mutations we could 
decisively conclude that they occurred as unique events in separate individuals 
based on a combination of the gender of the affected individual and the presence 
of additional de novo mutations (Table S10). Nevertheless, it might be possible 
that siblings of affected individuals were included who share a DNM due to 
parental gonadal mosaicism.137  Alternatively, DNMs might occur multiple times in 
disease cohorts as a consequence of a locally increased mutation rate. Examples 
of the latter might for instance incur a selective growth advantage (i.e. selfish 
mutations138) and thereby result in a pattern of mutational clustering such as 
known for FGFR2 (MIM: 176943) mutations in Apert syndrome (MIM: 101200).138 
However, biological relevance for the mutations in the identified genes in the 
context of ID/DD is suggested by the fact that in our control cohort genes with 
significant clusters were absent, and that for the majority of our identified genes 
experimental evidence in literature supports a NHI mutational mechanism (Table 
S11).
We hypothesized that the clustering de novo missense mutations of the 15 genes 
might exert their effects through mechanisms other than haploinsufficiency. To 
validate this hypothesis, we compiled a set of 116 genes known for mutations 
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that exert disease through non-haploinsufficient (NHI) mechanisms. Hereto, 
we selected for genes that have a “confirmed” status in the DDG2P list, or are 
present on both the Radboudumc ID/DD diagnostic testing and DDG2P lists 
(irrespective of the DDG2P status). Furthermore, genes were selected to be (i) 
dominant (mono-allelic), with the pathophysiological mechanism being either 
“activating”, “all missense/in frame” and/or “dominant negative” (Table S12). In 
addition, we generated a set of 183 haploinsufficient genes for which mutations 
are associated with ID/DD from the DDG2P gene list by selecting “loss-of-function” 
as the “mutation consequence” and “mono-allelic” for the “allelic requirement” in 
the DDG2P gene list (Table S13). 
Interestingly, for eight of the 12 genes for which mutations are known to cause ID/
DD and for which we identified mutation clustering, the disease mechanism on 
the constructed gene list was reported to be NHI. For these eight genes, it is either 
gain-of-function or dominant negative, thereby showing statistical enrichment for 
NHI mechanisms (p=2.66E-03, Fisher’s exact test; Table S14 and S15). For two of 
the three remaining genes (GRIN2B [MIM:138252] and SMAD4 [MIM: 600993]) both 
HI and NHI consequences have been reported,139–142 suggesting that for mutations 
in these genes more complex genotype-phenotype relations might exist, where HI 
and NHI mechanisms cause clinically distinct ID/DD-related disorders. For KCNQ2 
(MIM: 602235), the reported mutational mechanism is HI although a literature 
search also revealed cases with dominant-negative effects.143 We also investigated 
the extent of the evidence for NHI mechanisms and found that extensive functional 
work of mutations supporting NHI mechanisms has been previously published for 
eight of the 12 known genes (Table S11).
Further we hypothesized that NHI genes should be depleted for truncating 
mutations in individuals with ID/DD, i.e. mutations resulting in premature 
translation termination, whereby the mRNA is targeted for nonsense mediated 
decay. In our initial analyses focusing on de novo missense mutations only, we 
excluded truncating mutations from our dataset. Retrospectively, we searched 
for truncating DNMs in the 15 identified genes with clustering de novo missense 
mutations. We found only three predicted truncating mutations in two of 15 genes, 
which is significantly less than expected based on the total number of DNMs found 
in the total cohort for all HI genes (p˂1.00e-05; Permutation test). 
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We have previously hypothesized that genes with mutations acting through 
NHI mechanisms might be more intolerant to normal variation than genes 
with mutations acting though a HI mechanism for ID/DD.70 To test for tolerance 
to variation, existing scores like pLI50 are not useful as these capture tolerance 
to mRNA truncating variation rather than tolerance to variation in general. 
Therefore, we measured tolerance to variation as the ratio of missense over 
synonymous variation ‘dN/dS’, which has been used by us and others previously for 
predicting disease genes.10,59,84 We downloaded all PASS-filtered single nucleotide 
variants (SNVs) from ExAC (n=9,035,134) and constructed a ‘dN/dS’ measure by 
counting the unique missense SNVs missenseobs, and the unique synonymous 
SNVs synonymousobs, while correcting for sequence composition using the total 
possible unique missense and synonymous SNVs (missensebg and synonymousbg 
respectively)(Table S16): 
 
Based on calculations of these scores for the sets of 116 NHI, and 183 HI genes, 
we indeed find that genes with mutations acting through a NHI mechanism are 
significantly more intolerant to missense variation than genes with mutations 
acting though a HI mechanism (p=2.24e-03; permutation test, Figure 2). In line with 
our hypothesis, also our set of 15 genes with clustered DNMs was significantly less 
tolerant to missense variation compared to the set of 183 genes with mutations 
acting through a HI mechanism (p=8.45e-03; permutation test, Figure 2). 
Chapter 4
86
Figure 2. Intolerance to Missense Variation
Violin plots show the distribution of the gene-based dN/dS (y axis) per gene set (x axis). The median 
dN/dS is indicated by a red horizontal line. The NHI genes are more intolerant to missense variation 
than HI genes (HI genes median: 0.460; NHI genes median: 0.428; p = 2.24e-03). In addition, the 
identified genes with clustering mutations are more intolerant to missense variation than HI genes 
(genes with clustering mutations median: 0.352; p = 8.45e-03).
▶Figure 3. Examples of Modeling of Missense Mutations on 3D Protein Structures
Wild-type residues are marked in blue; de novo mutations are indicated as red globes or lines 
(Tables S17).
A. 3D structure of GNA1, acting through HI, showing that the modeled missense mutations are 
buried and likely to disrupt protein folding.
B. Structure of PPP2R5D, acting through NHI, where the modeled missense mutations affect 
mostly surface residues and are expected to have no or only local structural effects.
C. Zoom-in of known missense variants p.Arg496Cys and p.Ile500Val in SMAD4 known to act 
through a gain-of-function mechanism. These variants are located on the surface of the monomer 
and in contact with another SMAD4 monomer.141
D. Zoom-in of the missense variant p.Gly343Arg in ACTL6B which is located at the surface. The 
side-chain points toward the solvent, therefore the larger Arginine will fit.
E. Zoom-in of the missense variant p.Pro65Leu in PCGF2 close to the interaction site with other 
molecules.





Modeling of missense mutations in a 3D protein structure is helpful to gain 
more insight into the possible structural and functional effects.144 Conceptually, 
mutations in the core of the protein structure are more likely to prevent proper 
folding than mutations on the protein surface.145 The impact of a surface change 
however depends entirely on the spatial context and is therefore less likely to 
result in misfolding and subsequent protein degradation.146 Consequently, de 
novo disease-causing missense mutations preventing proper folding cause protein 
degradation, and thus indirectly lead to HI, similar to protein truncating mutations 
in such genes. To test the hypothesis that our clustered de novo missense mutations 
do not generally result in HI due to protein misfolding we modeled mutations onto 
the 3D protein structure using YASARA & WHAT IF Twinset.14,147 A (partial) protein 
3D structure was available or could be created via homology modeling for 10 of 
the 15 identified genes. We assessed 48 missense mutations on the 3D structure 
(i.e. buried, at the surface, or semi-buried) and whether the mutation was likely to 
affect protein folding (no effect, local effect, or large effect; Figure 3, Table S17). 
To compare the results of 3D modeling of clustered mutations, we also modeled 
75 de novo disease-causing missense mutations in 25 genes with mutations acting 
though HI (Table S13) for which a structure was available (Table S17). For the 
HI genes, 42% of missense mutations were buried and 34% of mutations were 
located at the protein surface. In the 10 genes for which a mutational NHI effect 
is proposed, only 11% of mutations was buried whereas 61% was located at the 
protein surface (p=1.26E-03, chi-square test; Table S17). Even more strikingly, only 
19% of the clustering de novo missense mutations were likely to result in a large 
structural change that would affect protein function whereas this was observed 
for 63% of de novo missense mutations in HI genes (p = 8.43E-06, chi-square test). 
These results support the notion that the majority of clustered de novo disease-
causing missense mutations do not result in haploinsufficiency at the protein 
structure level, but enact their effect through other mechanisms. Possibly this 
could be through the functional impairment of protein-protein interactions, as we 
noted that two of the three candidate ID/DD genes require complex formation or 
joining of protein subunits (e.g. multimerisation) to be functional (Table 2).
In conclusion, we developed a method for the identification of disease genes based 
on the significance of spatial mutation clustering within a gene. We show that our 
method successfully identifies genes previously implicated in ID/DD. Moreover, 
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we identified three genes with similar clustering patterns that we propose as 
candidate ID/DD genes. Our findings support the concept that these mutations 
mostly exert their pathogenic effect through disease mechanisms other than 
haploinsufficiency. Thus, our findings might indicate a larger contribution of non-




All supplementary information can be found online with the published article at 
https://doi.org/10.1016/j.ajhg.2017.08.004




5Chapter 5Evidence for 28 genetic disorders discovered by combining healthcare and research data
Joanna Kaplanis1, Kaitlin E. Samocha1, Laurens van de Wiel1, Zhancheng Zhang1, 
Kevin J. Arvai, Ruth Y. Eberhardt, Giuseppe Gallone, Stefan H. Lelieveld, Hilary C. Mar-
tin, Jeremy F. McRae, Patrick J. Short, Rebecca I. Torene, Elke de Boer, Petr Danecek, 
Eugene J. Gardner, Ni Huang, Jenny Lord, Iñigo Martincorena, Rolph Pfundt, Margot R. 
F. Reijnders, Alison Yeung, Helger G. Yntema, DDD Study, Lisenka E. L. M. Vissers, Jane 
Juusola, Caroline F. Wright, Han G. Brunner, Helen V. Firth, David R. FitzPatrick, Jeffrey 
C. Barrett, Matthew E. Hurles2, Christian Gilissen2, Kyle Retterer2
1, 2: These authors contributed equally
Published in Nature 




De novo mutations in protein-coding genes are a well-established cause of 
developmental disorders.114 However, genes known to be associated with 
developmental disorders account for only a minority of the observed excess of 
such de novo mutations.114,148 Here, to identify previously undescribed genes 
associated with developmental disorders, we integrate healthcare and research 
exome-sequence data from 31,058 parent–offspring trios of individuals with 
developmental disorders, and develop a simulation-based statistical test to 
identify gene-specific enrichment of de novo mutations. We identified 285 genes 
that were significantly associated with developmental disorders, including 28 
that had not previously been robustly associated with developmental disorders. 
Although we detected more genes associated with developmental disorders, 
much of the excess of de novo mutations in protein-coding genes remains 
unaccounted for. Modelling suggests that more than 1,000 genes associated with 
developmental disorders have not yet been described, many of which are likely 
to be less penetrant than the currently known genes. Research access to clinical 
diagnostic datasets will be critical for completing the map of genes associated with 
developmental disorders.
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It has previously been estimated that around 42–48% of patients with a severe 
developmental disorder (DD) have a pathogenic de novo mutation (DNM) in a 
protein-coding gene.114,148 However, most of these patients remain undiagnosed 
despite the identification of hundreds of DD-associated genes. This indicates that 
there are more DD-relevant genes to find. Existing methods to detect the gene-
specific enrichment of damaging DNMs do not incorporate all of the available 
information about which variants are more likely to be disease-associated; 
missense variants and protein-truncating variants (PTVs) vary in their impact on 
protein function.11,29,149,150 Known dominant DD-associated genes are strongly 
enriched in the minority of genes that exhibit strong selective constraint on 
heterozygous PTVs.50 To identify additional DD-associated genes, we need to 
increase our power to detect gene-specific enrichments of damaging DNMs by 
both increasing sample sizes and improving our statistical methods. In previous 
studies of pathogenic copy number variations, the use of healthcare data has 
been key to achieve larger sample sizes than would be possible in a research 
setting alone.151,152
Identification of 285 DD-associated genes
Following clear consent practices and only using aggregate, deidentified data, we 
pooled DNMs from patients with a DD from three centres: GeneDx (a US-based 
diagnostic testing company), the Deciphering Developmental Disorders study 
and Radboud University Medical Center. We performed stringent quality control 
on variants and samples to obtain 45,221 coding and splicing DNMs in 31,058 
individuals (Supplementary Fig. 1; Supplementary Table 1), including data 
on 24,348 trios that have not previously been published. These DNMs included 
40,992 single-nucleotide variants (SNVs) and 4,229 insertions or deletions (indels). 
The three cohorts have similar clinical characteristics, male-to-female ratios, 
enrichments of DNMs by mutational class and prevalences of known disorders 
(Supplementary Fig. 2). 
To detect gene-specific enrichments of damaging DNMs, we developed a 
method named DeNovoWEST (De Novo Weighted Enrichment Simulation Test, 
https://github.com/queenjobo/DeNovoWEST). DeNovoWEST scores all classes 
of sequence variants on a unified severity scale based on empirically estimated 
positive predictive values of being pathogenic (Supplementary Fig. 3, 4). We 
perform two tests per gene: an enrichment test on all nonsynonymous DNMs 
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and a test designed to detect genes that probably act through an altered-function 
mechanism, which combines a missense enrichment test with a missense clustering 
test. We then applied a Bonferroni multiple-testing correction accounting for the 
number of genes (n = 18,762) and two tests per gene.
We first applied DeNovoWEST to all individuals in our cohort and identified 281 
significantly enriched genes, 18 more than when using our previously published 
method114 (Figure 1a; Supplementary Fig. 5). The majority (196 out of 281; 70%) of 
the significantly enriched genes already had sufficient evidence of an association 
with DDs to be considered of diagnostic utility (as of late 2019) by all three centres, 
and we refer to these genes as ‘consensus’ genes. A further 54 out of 281 of the 
significantly enriched significant genes were previously considered diagnostic by 
one or two centres (‘discordant’ genes). Applying DeNovoWEST to synonymous 
DNMs, as a negative control analysis, identified no significantly enriched genes 
(Supplementary Fig. 6). 
To discover novel DD-associated genes with greater power, we applied 
DeNovoWEST to DNMs in patients without damaging DNMs in consensus genes 
(we refer to this subset as ‘undiagnosed’ patients) and identified 94 significant 
genes (Supplementary Fig. 7; Supplementary Table 2), of which 33 were 
putative ‘novel’ DD-associated genes. To ensure robustness to potential mutation 
rate variation between genes, we determined whether any of the putative novel 
DD-associated genes had significantly more synonymous variants in the Genome 
▶Figure 1: Results of DeNovoWEST analysis. A. Comparison of P values using DeNovoWEST 
versus the previous published method (mupit),114 run on the full cohort. Dashed lines indicate 
the threshold for genome-wide significance (one-sided, Bonferroni correction). Point size is 
proportional to the number of nonsynonymous DNMs in our cohort. The number of genes that 
fall into each quadrant are annotated. B. The number of missense and PTV DNMs in the novel 
genes. Point size is proportional to the –log10 (P) value of the analysis of the undiagnosed subset. 
Point colour corresponds to which test P value was more significant: blue, the nonsynonymous 
enrichment test (pEnrich); red, the missense enrichment and clustering test (pMEC). H3-3A is also 
known as H3F3A. C. The distribution of significant P values from analysis of the undiagnosed 
subset for discordant and novel genes; P values for consensus genes come from the full cohort 
analysis. The number of genes in each P-value bin is coloured by diagnostic gene group (n = 285 
significant genes; one-sided Bonferroni-corrected P values). D. The fraction of patients (n = 31,058) 
with a nonsynonymous mutation in each diagnostic gene group. Green, the remaining fraction 
of patients (the offspring of the parent–offspring trios) expected to have a pathogenic de novo 
coding mutation; grey, the fraction of patients that are likely to be explained by other factors. E. 
The fraction of patients with a nonsynonymous mutation in each diagnostic gene group split by 
sex (n = 13,636 female patients; n = 17,422 male patients). In all panels, black, blue and orange 
represents consensus, discordant and novel genes, respectively.





Aggregation Database (gnomAD)51 of population variation than expected under 
our null mutation model. We identified 11 out of 33 genes with a significant excess 
of synonymous variants. For these 11 genes, we repeated the DeNovoWEST 
test, increasing the null mutation rate by the ratio of observed to expected 
synonymous variants in gnomAD. Five of these genes fell below our exome-wide 
significance threshold and were removed, leaving 28 novel genes, with a median 
of 10 nonsynonymous DNMs (Fig. 1c; Supplementary Table 3). There were 314 
patients with nonsynonymous DNMs in these 28 genes (1.0% of our cohort); all of 
these DNMs were inspected in the Integrative Genomics Viewer (IGV)153 and, of the 
198 patients for which experimental validation was attempted, all variants were 
confirmed to be DNMs. The DNMs in these novel genes were distributed randomly 
across the three datasets (no genes with P < 0.001, heterogeneity test). In addition, 
6 of the 28 novel DD-associated genes were corroborated by OMIM entries or 
publications, including TFE3, which was described in two recent publications.154,155
We also investigated whether some of the synonymous DNMs might be pathogenic 
by disrupting splicing. We identified a small but significant enrichment of 
synonymous DNMs with high values of the splicing pathogenicity score SpliceAI156 
(≥ 0.8, 1.56-fold enriched, P = 0.0037, Poisson test; Supplementary Table 4). This 
enrichment corresponds to an excess of around 15 splice-disrupting synonymous 
DNMs in our cohort, of which 6 are accounted for by a recurrent synonymous 
DNM in KAT6B that is known to disrupt splicing.157
Taken together, 25.0% of our cohort has a nonsynonymous DNM in one of the 
consensus or significant DD-associated genes (Fig. 1d We noted significant sex 
differences in the autosomal burden of nonsynonymous DNMs (Supplementary 
Fig. 8). The rate of nonsynonymous DNMs in consensus autosomal genes was 
significantly higher in female individuals than male individuals (OR = 1.16, P = 4.4 x 
10-7, Fisher’s exact test; Fig. 1e), as noted previously.114 However, the exome-wide 
burden of autosomal nonsynonymous DNMs in all genes was not significantly 
different between undiagnosed male and female participants (OR = 1.03, P = 0.29, 
Fisher’s exact test). This indicates that there are subtle sex differences in the genetic 
architecture of DDs, especially with regard to known and undescribed disorders. 
This could include sex-biased contributions of polygenic, oligogenic and/or 
environmental modifiers of phenotypic variation and thus clinical ascertainment.
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Characteristics of the novel DD-associated genes
Based on semantic similarity158 between human phenotype ontology terms, 
patients with DNMs in the same novel DD-associated gene were less phenotypically 
similar to each other, on average, than patients with DNMs in a consensus gene 
(P = 2.3 x 10-11, Wilcoxon rank-sum test; Fig. 2a and Supplementary Fig. 9). This 
suggests that these novel disorders less often result in distinctive and consistent 
clinical presentations, which may have made these disorders more difficult to 
discover using a phenotype-driven approach. Each of these novel disorders 
requires genotype–phenotype characterization, which is beyond the scope of this 
study. 
Overall, novel DD-associated genes encode proteins that have very similar functional 
and evolutionary properties to consensus genes (Fig. 2b; Supplementary Table 
5). Despite the high-level functional similarity between known and novel DD-
associated genes, nonsynonymous DNMs in the more recently described DD-
associated genes are much more likely to be missense DNMs, and less likely to 
be PTVs (discordant and novel; P = 1.2 x 10-25, chi-squared test). Of the 28 novel 
genes, 15 (54%) had only missense DNMs. As a consequence, we expect that the 
effects of a greater proportion of the novel genes act through altered-function 
mechanisms 
Figure 2: Properties of the novel genes. A. The phenotypic similarity of patients with DNMs in 
novel and consensus genes. Random phenotypic similarity was calculated from random pairs of 
patients. Patients with DNMs in the same novel gene were less phenotypically similar than patients 
with DNMs in the same consensus gene P = 2.3 x 10-11, Wilcoxon rank-sum test). B. Comparison of 
properties of consensus (n = 380) and novel (n = 28) DD-associated genes known to be differential 
between consensus and non-DD-associated genes (95% bootstrapped confidence intervals are 
shown). GO, Gene Ontology; GERP, genomic evolutionary rate profiling; RPKM, reads per kilobase 
of transcript per million mapped reads; CDS, coding sequence; dN/dS, the ratio of substitution rate 
at nonsynonymous and synonymous sites.
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(for example, as dominant-negative or gain-of-function disorders). For example, 
the novel gene PSMC5 (DeNovoWEST P = 2.6 × 10−15) had one in-frame deletion 
and nine missense DNMs, eight of which altered two structurally important amino 
acids in the AAA+ ATPase domain; the effect of PSMC5 alterations are therefore 
probably generated through an altered-function mechanism (Supplementary Fig. 
10 a, b). None of the novel genes exhibited significant clustering of de novo PTVs.
We observed that missense DNMs were more likely to affect functional protein 
domains than other coding regions. We observed a 2.63-fold enrichment (P = 2.2 x 
10-68, G-test) in missense DNMs that reside in protein domains among consensus 
genes and a 1.80-fold enrichment (P = 8.0 x 10-5, G-test) in novel DD-associated 
genes, but no enrichment in synonymous DNMs (Supplementary Table 6). 
Four protein domain families in consensus genes were enriched in missense 
DNMs (Supplementary Table 7): ion transport protein (PF00520, P = 6.9 x 10-
4, Bonferroni-corrected G-test), ligand-gated ion channel (PF00060, P = 4.0 x 10-
6), and protein kinase domain (PF00069, P = 0.043) and kinesin motor domain 
(PF00225, P = 0.027). Missense DNMs in all four enriched domain families have 
previously been associated with DDs (Supplementary Table 8).159–161
We observed a significant overlap between the 285 DNM-enriched DD-associated 
genes and a set of 369 previously described cancer-driving genes162 (overlap of 70 
genes; p = 1.7 x 10-49, logistic regression correcting for selection on heterozygous 
PTVs (shet)), as observed previously,
163,164 as well as a significant enrichment in 
nonsynonymous DNMs in both overlapping and non-overlapping cancer genes 
(Supplementary Table 9). We observe 117 DNMs in 76 recurrent somatic mutations 
that were observed in at least three patients in The Cancer Genome Atlas (TCGA).165 
By modelling the germline mutation rate of these somatic driver mutations, we 
found that recurrent nonsynonymous mutations in the TCGA are enriched 21-fold 
in our cohort (p < 10-50, Poisson test, Supplementary Fig. 11), whereas recurrent 
synonymous mutations in the TCGA are not significantly enriched (2.4-fold, p = 
0.13, Poisson test). These results suggest that this observation is driven by the 
pleiotropic effects of these mutations in development and tumorigenesis, rather 
than because of hypermutability of these variants.




We identified 773 recurrent DNMs (736 SNVs and 37 indels), observed in 2–36 
individuals, which enabled us to systematically interrogate the factors that drive 
recurrent germline mutations. We considered three potential contributory factors: 
(1) clinical ascertainment that enriches for pathogenic mutations; (2) greater 
mutability at specific sites; and (3) positive selection that confers a proliferative 
advantage in the male germline.166 We observed evidence that all three factors 
contributed to the occurrence of recurrent germline mutations; however, these 
factors are not mutually exclusive. Clinical ascertainment drives the observation 
that 65% of recurrent DNMs were in consensus genes, a 5.4-fold enrichment 
compared with DNMs that were observed only once (p < 10-50, proportion test). 
Hypermutability underpins the observation that 64% of recurrent de novo SNVs 
occurred at hypermutable CpG dinucleotides,167 a 2.0-fold enrichment over DNMs 
that were observed only once (p = 3.3 x 10-68, chi-squared test).
Positive germline selection can increase the apparent mutation rate more 
strongly166 than either clinical ascertainment (10-100X in our dataset) or 
hypermutability (around 10× for CpGs). However, only a minority of the most 
highly recurrent mutations in our dataset are in genes that have been previously 
associated with germline selection. Nonetheless, several lines of evidence 
suggested that the majority of these most highly recurrent mutations are likely 
to confer a germline selective advantage. On the basis of the observations above, 
DNMs under germline selection should be more likely to be activating missense 
mutations, and should be less enriched for CpG dinucleotides. Extended Data 
Table 1 shows the 16 de novo SNVs that were observed 9 or more times in our 
cohort, only 2 of which are in known germline selection genes. All but 2 of these 
16 de novo SNVs cause missense changes, all but 2 of these genes cause disease 
by an altered-function mechanism, and these DNMs were depleted for CpGs 
relative to all recurrent mutations. Two of these genes with highly recurrent de 
novo SNVs, in SHOC2 and PPP1CB, which encode interacting proteins that regulate 
the RAS–MAPK pathway; pathogenic variants in these genes are associated with a 
Noonan-like syndrome.168 Moreover, two of these recurrent DNMs are in the same 
gene (SMAD4), which encodes a key component of the TGFβ signalling pathway, 
potentially expanding the pathophysiology of germline selection beyond the RAS–
MAPK pathway. Confirming germline selection of these mutations will require 
deep sequencing analyses of the testes and/or sperm.169
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Extended Data Table 1. De novo SNVs with more than nine recurrences in our cohort annotated 
with relevant information, such as CpG status, whether the affected gene is a known somatic 
driver or germline-selection gene, and diagnostic gene group (for example, consensus). ‘Recur’ 
refers to the number of recurrences. ‘Likely mechanism’ refers to the mechanisms attributed to 
this gene in the published literature. 
Incomplete penetrance and pre- or perinatal death
Nonsynonymous DNMs in consensus or significant DD-associated genes accounted 
for half of the exome-wide nonsynonymous DNM burden associated with DD (Fig. 
1b). Despite our identification of 285 significantly DD-associated genes, there 
remains a substantial burden of both missense and protein-truncating DNMs in 
unassociated genes (those that are neither significant in our analysis nor on the 
consensus gene list). This residual burden of protein-truncating DNMs is greatest 
in genes that are intolerant to PTVs in the general population (Supplementary 
Fig. 12), which suggests that many haploinsufficient disorders have not yet been 
described. We observed that PTV mutability (estimated from a null germline 
mutation model) was significantly lower in unassociated genes compared with 
DD-associated genes (p = 4.5 x 10-68 Wilcox rank-sum test; Fig. 3a), which leads 
to reduced statistical power to detect DNM enrichment in unassociated genes, 
consistent with our hypothesis that numerous haploinsufficient disorders have 
not yet been identified.
A key parameter in estimating statistical power to detect novel haploinsufficient 
disorders is the fold enrichment of de novo PTVs expected in undescribed 
haploinsufficient disorders. We observed that novel DD-associated haploin-
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Figure 3: Factors that influence power to detect DD-associated genes. 
A. PTV mutability is significantly lower (p = 4.6 x 10-68, two-sided Wilcox rank-sum test) in genes 
that are not significantly DD-associated (blue) than in DD-associated genes (red). Median is shown 
as a black horizontal line. bp, base pairs. B. Distribution of PTV enrichment in significant, likely 
haploinsufficient genes by category (118 consensus, 23 discordant and 8 novel genes). Lower 
and upper hinges correspond to first and third quartiles. Median is shown by a horizontal grey 
line. The upper and lower whiskers extend 1.5× the interquartile range. C. Comparison of PTV 
enrichment in our cohort compared with the PTV to synonymous (syn) ratio in gnomAD, for genes 
that are significantly PTV-enriched in our cohort (without variant weighting; n = 156 genes). PTV 
enrichment bins are calculated as log10 (enrichment). The dashed line shows the regression line. 
Confidence intervals are the 95% intervals of the rate ratio. d, Overall PTV enrichment across 
genes grouped by the likelihood of individuals showing a structural malformation on a prenatal 
ultrasound (145 low, 65 medium, 6 high genes). PTV enrichment is significantly higher for genes 
with a low likelihood compared to other genes (p = 4.6 x 10-5, two-sided Poisson test). Poisson 95% 
confidence intervals are shown.
sufficient genes had significantly lower PTV enrichment compared with the 
consensus haploinsufficient genes (p = 0.005, Wilcoxon rank-sum test; Fig. 3b). Two 
additional factors that could lower DNM enrichment, and thus the power to detect 
a novel DD association, are reduced penetrance and increased pre- or perinatal 
death (due to spontaneous fetal loss, termination of pregnancy because of a fetal 
anomaly, stillbirth or early neonatal death). To evaluate incomplete penetrance, 
we investigated whether haploinsufficient genes with a lower enrichment of de 
novo PTVs in our cohort are associated with a greater prevalence of PTVs in the 
general population. We observed a significant negative correlation (p = 0.031, 
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weighted linear regression) between PTV enrichment in our cohort and the ratio 
of PTV to synonymous variants in gnomAD149, which suggests that incomplete 
penetrance does lower de novo PTV enrichment in our cohort (Fig. 3c).
Additionally, we observed that the fold enrichment of de novo PTVs in consensus 
haploinsufficient DD-associated genes in our cohort was significantly higher 
for genes with a low likelihood of presenting with a structural malformation of 
the fetus during prenatal screening (p = 4.6 x 10-5, Poisson test, Fig. 3d), which 
indicates that pre- or perinatal death decreases our power to detect some of the 
novel disorders (see Supplementary Information for details).
Hundreds of DD genes have not yet been discovered
Downsampling of our cohort and repeating enrichment analyses showed that 
the discovery of DD-associated genes has not plateaued (Extended Data Fig. 
1a). Increasing the sample size should result in the discovery of many novel DD-
associated genes. To estimate how many haploinsufficient genes have not yet been 
described, we modelled the likelihood of the observed distribution of de novo PTVs 
among genes as a function of varying numbers of undiscovered haploinsufficient 
DD-associated genes and fold enrichments of de novo PTVs in those genes. We 
found that the remaining PTV burden is most likely spread across around 1,000 
genes with an approximately 10-fold PTV enrichment (Extended Data Fig. 1b). 
This fold enrichment is three times lower than in known haploinsufficient DD-
associated genes, which suggests that incomplete penetrance and/or pre- or 
perinatal death is more prevalent among undiscovered haploinsufficient genes. 
We modelled the missense DNM burden separately and also observed that 
the most likely architecture of undiscovered DD-associated genes is one that 
comprises more than 1,000 genes with a substantially lower fold enrichment than 
in currently known DD-associated genes (Supplemental Fig. 13). 
We calculated that a sample size of around 350,000 parent–offspring trios would 
be needed to have 80% power to detect a tenfold enrichment of de novo PTVs 
for an average gene. Using this inferred tenfold enrichment among undiscovered 
haploinsufficient genes, from our current data we can evaluate the likelihood that 
any gene i is an undiscovered haploinsufficient gene, by comparing the likelihood 
of the number of de novo PTVs observed in each gene to have arisen from the 
null mutation rate or from a tenfold increased PTV rate. Among the approximately 
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19,000 non-DD-associated genes, around 1,200 were more than three times more 
likely to have arisen from a tenfold increased PTV rate, whereas approximately 
7,000 were three times more likely to have no de novo PTV enrichment.
Extended Data Fig. 1 Exploring the remaining number of DD genes.
a, Number of significant genes after downsampling the full cohort and running the enrichment 
test of DeNovoWEST. b, The likelihood of the observed distribution of de novo PTV mutations 
was modelled. This model varies the numbers of remaining haploinsufficient (HI) DD genes and 
PTV enrichment in those remaining genes. The 50% credible interval is shown in red and the 
90% credible interval is shown in orange. Note that the median PTV enrichment in genes that 
are significant and known to operate through a loss-of-function mechanism (as indicated by an 
arrow) is 39.7.
Discussion
Here we describe 28 novel developmental disorders by developing an improved 
statistical test for mutation enrichment and applying it to a dataset of exome 
sequences from 31,058 parent–offspring trios. Most of the increased power to 
detect novel disorders comes from the increase in sample size, rather than the 
improved statistical test. These 28 novel genes account for 1.0% of our cohort, and 
their inclusion in diagnostic workflows will help to improve diagnosis of similar 
patients globally. The value of this study for improving diagnostic yield extends 
beyond these 28 novel genes; the total number of genes added to diagnostic 
workflows of the three participating centres (including newly validated discordant 
genes) ranged from 48 to 65 genes. We show that both incomplete penetrance 
and pre- or perinatal death reduced our power to detect novel DDs postnatally, 
and hypothesize that one or both of these factors are operating more strongly 
among undiscovered DD-associated genes. In addition, we identify a set of highly 
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recurrent mutations that are strong candidates for novel germline selection 
mutations, which should result in a higher than expected disease incidence that 
increases markedly with increased paternal age.
Our study is approximately three times larger than a recent meta-analysis of DNMs 
from a collection of individuals with autism spectrum disorder, intellectual disability 
and/or a developmental disorder.170 We identified around 2.3 times as many 
significantly DD-associated genes as this previous study when using Bonferroni-
corrected exome-wide significance (285 compared with 124). In contrast to meta-
analyses of published DNMs, the harmonized filtering of candidate DNMs across 
cohorts in this study should be more robust to cohort-specific differences in the 
sensitivity and specificity of detecting DNMs.
We inferred indirectly that developmental disorders with higher rates of 
detectable prenatal structural abnormalities had a greater likelihood of pre- 
or perinatal death. The potential size of this effect can be quantified from the 
recently published PAGE study of genetic diagnoses in a cohort of fetal structural 
abnormalities.171 In the PAGE study, genetic diagnoses were not returned to 
participants during the pregnancy, and so genetic diagnostic information could 
not influence the incidence of pre- or perinatal death. In the PAGE study data, 
69% of fetal abnormalities with a genetically diagnosable cause died perinatally 
or neonatally. This emphasizes the substantial effect that pre- or perinatal death 
can have on reducing the ability to discover novel DDs from postnatal recruitment 
alone, and motivates the integration of genetic data from prenatal, neonatal and 
postnatal studies in future studies.
To empower our mutation enrichment testing, we estimated positive predictive 
values that each DNM was pathogenic on the basis of their predicted protein 
consequence, CADD score,29 selective constraint against heterozygous PTVs across 
the gene (shet
172), and, for missense variants, presence in a region under selective 
missense constraint.11 These positive predictive values should also be informative 
for variant prioritization in the diagnosis of dominant developmental disorders. 
Further work is needed to investigate whether these positive predictive values 
could be informative for recessive developmental disorders, and in other types of 
dominant disorders. More generally, we hypothesize that empirically estimated 
positive predictive values based on variant enrichment in large datasets will be 
similarly informative in many other disease areas.
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We adopted a conservative statistical approach to identifying DD-associated 
genes. In two previous studies using the same significance threshold, we identified 
26 novel DD-associated genes.109,114 All 26 are now regarded as being diagnostic, 
and have entered routine clinical diagnostic practice. Had we used a significance 
threshold with a false-discovery rate of <10% as used previously,173 we would 
have identified 770 DD-associated genes. The false-discovery rate of individual 
genes depends on the significance of other genes being tested, which means that 
it is not appropriate for assessing the significance of individual genes, but can be 
useful for defining gene sets. There are 184 consensus genes that did not cross 
our significance threshold in this study. It is likely that many of these genes cause 
disorders that were underrepresented in our study due to the ease of clinical 
diagnosis on the basis of distinctive clinical features or targeted diagnostic testing. 
These ascertainment biases will not affect the representation of novel DDs in our 
cohort.
Our modelling suggests that there are probably more than 1,000 DD-associated 
genes that remain to be discovered, and that reduced penetrance and pre- or 
perinatal death will reduce our power to identify these genes using DNM 
enrichment. Identifying these genes will require both improved analytical methods 
and greater sample sizes. As sample sizes increase, accurate modelling of gene-
specific mutation rates becomes more important. In our analyses of 31,058 trios, 
we observed evidence that mutation rate heterogeneity among genes can lead 
to overestimation of the statistical significance of mutation enrichment based on 
an exome-wide mutation model. We advocate the development of more granular 
mutation rate models, based on large-scale population variation resources, that 
correct for all technical and biological complexities, to ensure that larger studies 
are robust to mutation rate heterogeneity.
We anticipate that the variant-level weights used by DeNovoWEST will improve 
over time. As reference population samples, such as gnomAD,149 increase in 
size, weights based on selective constraint metrics (for example, shet or regional 
missense constraint) will improve. Weights could also incorporate more functional 
information, such as expression in disease-relevant tissues. For example, we 
observe that DD-associated genes are significantly more likely to be expressed 
in the fetal brain (Supplementary Fig. 14). Furthermore, new metrics based on 
gene co-regulation networks can predict whether genes function within a disease-
relevant pathway.174 As a cautionary note, including more functional information 
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may increase power to detect some new disorders while decreasing power for 
disorders with a pathophysiology that is different from known disorders. Our 
analyses also suggest that variant-level weights could be further improved by 
incorporating other variant prioritization metrics, such as upweighting variants 
predicted to affect splicing, variants in particular protein domains or variants that 
are somatic driver mutations during tumorigenesis. In developing DeNovoWEST, 
we explored the application of both variant-level weights and gene-level weights 
in separate stages of the analysis; however, subtle but pervasive correlations 
between gene-level metrics (for example, shet) and variant-level metrics (for 
example, regional missense constraint or CADD) present statistical challenges 
to implementation. Finally, the discovery of less penetrant disorders can be 
empowered by analytical methodologies that integrate both DNMs and rare 
inherited variants, such as TADA.175 Nonetheless, using current methods focused 
on DNMs alone, we estimated that around 350,000 parent–child trios would need 
to be analysed to have around 80% power to detect haploinsufficient genes with 
a tenfold PTV enrichment. Discovering non-haploinsufficient disorders will need 
even larger sample sizes. Reaching this number of sequenced families will not be 
possible for an individual research study or clinical centre; it is therefore essential 
that genetic data generated as part of routine diagnostic practice are shared 
with the research community such that it can be aggregated to drive discovery of 
previously undescribed disorders and improve diagnostic practice.




All supplementary information can be found online with the published article at 
https://doi.org/10.1038/s41586-020-2832-5
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Variant interpretation remains one of the major challenges in medical genetics. 
Previously we showed how genetic variation, when aggregated over homologous 
protein domains, help interpret variants of unknown significance. Here, we 
created the Meta-Domain HotSpot (MDHS) p-value to identify mutation hotspots 
in homologous domains. The MDHS p-value was used to identify hotspots of de 
novo mutations (DNMs) in a dataset of 45,221 DNMs from 31,058 patients with 
developmental disorders (DDs). Of these, 15,392 DNMs locate to evolutionary 
equivalent positions in protein domain regions across 6,910 genes.The MDHS 
p-value identified three missense DNM hotspots, and no hotspots for synonymous 
or nonsense DNMs. All missense DNM hotspots are in the ion transport protein 
domain family (PF00520). The 57 missense DNMs driving enrichment result from 
25 genes, of which 19 were previously associated to DDs. Function altering disease-
mechanisms have been described for some of the DNMs at these hotspots in 
literature. 3D Protein structure modelling of the 25 genes consistently confirmed 
the same function of the native residues at each of these hotspots. One hotspot 
is located at the ion channel gate and the other two at voltage-sensing positions 
critical for the in/activation of the ion channel. Therefore all DNMs at these 
hotspots are function-altering and likely pathogenic. Six genes (CACNA1B, TPCN1, 
TPCN2, KCNH5, KCNG1, and TRPM5) are now suggested as new candidate genes for 
DD based on DNMs at these hotspots. In conclusion, we show a novel approach to 
identify candidate disease genes based on homologous protein domain mutation 
hotspots.
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De novo mutations (DNMs) in protein-coding genes are an established cause for 
developmental disorders (DDs).176 An estimated 2-5% of all children are born 
with severe DDs in the form of congenital malformations or neurodevelopmental 
disorders.177,178 Of these, ~42-48% are caused by a DNM in a protein-coding 
gene.114,148 On average, any individual has about 1-2 DNMs in protein-coding 
regions.59 Statistical models use this to identify DNM enrichment in patient 
cohorts that point to candidate disease-causing genes. These efforts have 
resulted in a growing number of genes that are now associated with DD, and has 
led to the publication of a growing collection of DNMs from patient cohorts with 
DDs.109,114,120,128,179 Nevertheless, DD-association of genes has far from saturated 
and over 1,000 DD-associated genes are expected to await discovery.179 To 
continue DD-association this way, larger and larger cohorts are required
The largest cohort of 31,058 patients with DDs was recently published in a study 
by Kaplanis et al. This enabled novel DD-association for 28 genes. Remarkably, 15 
of these genes were enriched by missense mutations only, suggesting that these 
genes may not act through a classical mechanism of haploinsufficiency. This could 
partly explain the difficulties in identifying novel DD genes, since the decreased 
mutational target would give rise to fewer patients with mutations in these genes, 
than would be expected if these genes were to act through haploinsufficiency. 
Non-haploinsufficient DD genes can be identified by mutation clustering patterns 
in particular gene regions.104,113 However, DNMs are rare and therefore these 
methods require large sample sizes to be successful. 
Protein domain regions are of particular interest, because ~71% of curated 
disease-causing missense variants in Human Gene Mutation Database (HGMD)91 
and ClinVar54 occur in protein domains.93 DD-associated missense DNMs are up 
to a 2.63 fold more likely to be found in these regions.179 It has been shown that 
the evolutionary conserved architecture underlying homologous protein domains 
can be used to aggregate genetic variation across the human genome.60,93,180–183 
Disease-causing missense variants aggregated to equivalent protein domain 
positions are depleted of population-based variation and vice versa.93 In addition, 
disease-causing missense variants on identical homologous protein domain 
positions, modelled in yeast, result in similar disease-phenotypic changes.181
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We developed a novel methodology to perform mutation clustering of DNMs 
across homologous protein domains. By aggregating across homologs we increase 
the statistical power to identify mutation clusters. Using this method on DNMs 
from 31,058 patients with DDs and suggest novel disease gene candidates.
Materials and Methods
Dataset of de novo mutations and developmental disorder diagnostic 
gene lists
We obtained all 45,221 DNMs from the Kaplanis et al study.179 These DNMs 
were identified in 31,058 patients with DDs from three centres. The genetic 
testing approach of these patients were described previously per centre: DDD,114 
GeneDX,184 and, Radboudumc.128 All individuals that underwent genetic testing 
provided informed consent.179 Subset of these patients have been analysed and 
reported in previous publications.70,114,184,185 We also make use of the diagnostic 
lists of DD-associated genes from the Kaplanis et al. study, namely the novel 
(n=28), consensus (n=380) and discordant (n=607) diagnostic gene lists.179 
Annotation of transcript details, protein and meta-domain position 
annotation
The DNMs were annotated with corresponding GENCODE63 transcripts from 
release 19 GRCh37.p13 Basic set, protein information from UniProtKB/Swiss-Prot64 
Release 2016_09, Pfam-A41 v30.0 protein domains information, and meta-domain93 
positions using a local version of the MetaDome53 web server (code available 
at https://github.com/cmbi/metadome). Meta-domains are based on multiple 
sequence alignments of parts of human protein-coding genes that correspond 
to Pfam protein domain families. The genetic variants which correspond to 
homologous protein domain positions receive additional annotation of the 
corresponding Pfam domain ID and consensus position.
Filtering the annotated DNMs
The annotation process can result in multiple GENCODE gene transcripts per 
DNM. To ensure a single GENCODE transcript per gene we performed a filtering 
step by the following order of criteria:
De novo mutation hotspots in homologous protein domains
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1. Only keep variants that have the following transcript consequence: 
missense, synonymous, or, stop-gained 
2. The transcript corresponds to a human canonical or isoform entry in 
Swiss-Prot
3. This transcript contains all (or most) of the de novo mutations for the 
corresponding gene
4. The transcript translates to the longest protein sequence length
5. If multiple transcripts remain for a gene, one of these is selected
6. Filter variants only to those that are in a Pfam protein domain
Detection of variant hotspots in homologous protein domains
The Pfam domain ID in combination with the consensus position allows for 
aggregation of variants. Using these aggregated variants, we can identify which 
of the meta-domain positions are significantly enriched with variants. For this 
purpose we created the MDHS (Meta-Domain HotSpot) p-value to identify 
mutational hotspots in homologous protein domains defined as follows: 
MDHS p-value (1.)
In the context of meta-domains, n corresponds to the total number of aggregated 
genetic variants for the Pfam domain ID, L is the total number of possible 
consensus positions for a Pfam domain ID, k is the total number of genetic 
variants aggregated at a single consensus position, and, x = k - 1, which depicts the 
chance of finding less then observed genetic variants at the consensus position. 
The MDHS p-value is adapted from the mCluster183 and DS-Score186. In line with 
these methods, variants are assumed to follow a Binomial distribution. We correct 
the MDHS p-value via the Bonferroni method for the total number of Pfam protein 
domain IDs considered. If a Bonferroni corrected MDHS p-value <0.05 we consider 
it as a significant mutational hotspot.
We consider two ways of counting genetic variants to represent variable k in the 
MDHS p-value (Equation 1): an ‘unrestricted mutation count’ and a ‘restricted 
mutation count’ (Figure 1). The unrestricted mutation count would include every 
DNM, even when multiple DNMs occur at exactly the same chromosomal position 
Chapter 6
116
(i.e. recurrent DNMs). The restricted count considers mutated chromosomal 
positions only once, thereby reducing the impact of recurrent mutations at a 
single position in a gene.
Figure 1. Graphical example of the two ways we count mutations that are aggregated over 
homologous protein domain regions. On the left there are three protein representations of 
hypothetical genes A, B and C with the mutations displayed as red lollipops, the domains as blue 
and white boxes. The white boxes represent domains that are homologous and are extracted 
including their mutations and displayed on the right part of this image as domains A, B, and 
C. The mutations encountered in the domains are aggregated over corresponding homologous 
domain positions. The aggregated mutations are displayed as ‘unrestricted mutation count’, 
which includes all observed mutations. The ‘restricted mutation count’ counts uniquely occurring 
mutation per position. 
Protein 3D structural modelling
We have created structural homology models using YASARA & WHAT IF Twinset14,147 
of the Ion Transport protein domain regions for each of the 25 genes in which a 
DNM missense was located at the identified DNM missense hotspot. The locations 
of each missense DNM present at one of the hotspots have been coloured purple 
in the YASARA scenes and the remainder of the structures are grey (Supp. Data 
S1).




To identify hotspots of de novo mutations in protein domains, we count DNMs in 
a manner that reduces any mutational gene-bias (Figure 1), which then can be 
used to compute protein domain based positional enrichment (Equation 1) for 
each de novo variant type separately. We first mapped the original 45,221 DNMs 
resulting from 31,058 patients with developmental disorders from the Kaplanis 
et al.179 study onto gene transcripts (Methods). After this mapping, of the original 
DNMs 37,089 single nucleotide variants remained of which 15,322 are located on a 
total of 12,389 meta-domain positions. These 15,322 DNMs resulted from protein 
domain regions of 6,910 protein-coding genes, and these protein domain regions 
consist of 2,311 protein domain families. The distribution of variant types of these 
15,322 DNMs are ~73.7% missense, ~21.1% synonymous, and, ~5.3% stop-gained 
(Supp. Data S2; Supp. Table 1). 
Using all 15,322 DNMs in protein domains the MDHS p-value identified 32 
significant hotspots. These hotspots were enriched by 326 missense DNMs from 
16 protein domain families (Supp. Data S3). There were no synonymous or 
nonsense DNMs driving significant enrichment (Supp. Data S4 & S5). Upon close 
examination, we found 9 of these hotspots to be enriched due to a large numbers 
of DNMs located in a single gene codon. Meaning that gene-specific DNM burdens 
are be picked up via the MDHS method. To reduce the gene-specific DNM burden, 
we further filtered the 32 hotspots with the criteria that the DNMs driving their 
enrichment should span at least two different gene-codons. After this filtering, 
there remain 23 missense DNM hotspots in 12 protein domain families based on 
245 DNMs from 67 genes. Nineteen of these 67 genes were not associated to 
DDs in the Kaplanis et al. study, representing a 2.53-fold enrichment of known 
DD-associated genes (p = 1.26-31 chi-square test; Supp Table 2). This suggests that 
our approach could potentially point to new candidate DD genes. However, as this 
analysis picked up gene-specific DNM burdens, we cannot attribute the DNMs that 
drive hotspot enrichment as purely domain-specific. 
We repeated the hotspot discover analysis with a more restricted way of 
counting the DNMs to reduce gene-specific enrichment patterns being picked up 
(Figure 1). In this restricted counting analysis, the MDHS p-value identifies three 
significant hotspots comprised of 57 missense DNMs from 25 genes (Supp Data 
S6). Strikingly, all three hotspots are located in the Ion Transport protein domain 
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family (PF00520) (Figure 2). Again there are no hotspots revealed for synonymous 
and nonsense DNMs. The three significant hotspots are located on the domain 
consensus positions p.96 (10 DNMs, restricted MDHS p = 3.6 x 10-2, 16 DNMs 
unrestricted MDHS p= 1.7 x 10-6), p.102 (13 DNMs, restricted MDHS p = 7.1 x 10-
5, 20 DNMs, unrestricted MDHS p= 1.6 x 10-10), and p.231 (14 DNMs, restricted 
MDHS p = 8.0 x 10-6, 21 DNMs, unrestricted MDHS p= 1.4 x 10-11). The fact that all 
hotspots occur within the same domain family strengthens the hypothesis that 
these positions are likely of functional importance. The Ion Transport protein 
domain family is one of four protein domain families that we previously found 
to be significantly enriched with missense DNMs in genes that are associated to 
DDs.179 Of the 25 genes identified with a missense DNM at a hotspot, 19 were 
listed as diagnostic DD-associated gene in Kaplanis et al. representing a 3.17-fold 
enrichment of known DD-associated genes (p = 1.78 x 10-13 chi-square test; Supp 
Table S3). 
Figure 2. The restricted count distribution of missense DNMs aggregated over the Ion Transport 
protein domain family (PF00520). The total consensus length of this domain is 245 and the sum 
of the restricted count distribution is 350. The significance threshold is displayed as a dotted 
blue line, computed via the MDHS p-value (Equation 1). The bars that exceeded the significance 
threshold are colored in red and represent the mutational hotspots p.96, p.102, and, p.231.
We created 3D protein structure homology models for each of the 25 genes 
(Supp. Data S1). Then we analysed if the missense changes were at functionally 
important positions in the Ion Transport protein domain in each of these 3D 
structures (Supp. Data S7). There is a large 3D protein structural overlap between 
for the Ion transport protein domains, they are a 3-fold less diverse in structural 
conformation then their observed sequences (CATH-Gene3D ID: 1.20.120.350).187 
Due to the structural overlap, we validated if molecular effects of missense variants 
De novo mutation hotspots in homologous protein domains
6
119 
at these hotspots are likely to have similar impact on domain function across the 
25 genes. Using the 25 homology models we found that hotspot p.96 (Figure 3A) 
and p.102 (Figure 3B) are part of the voltage-sensing helix that is important for 
the channel in/activation.188 Hotspot p.231 (Figure 3C) is part of the channel gate 
at the end of the transmembrane helix (Supp. Data S7). In addition, we found 
that missense mutations follow a specific pattern for each of these hotspots. Of 
the 13/16 missense DNMs located at hotspot p.96 and 20/20 at p.102 change the 
positively charged wild-type residue to lose the positive charge. Losing positive 
charges at these locations has previously been described to trigger a function 
altering disease-mechanism (Figure 3A&B).189,190 At hotspot p.231 20/21 of the 
missense DNMs changes the wild-type residue from a small into a larger residue. 
This change in residue size likely impacts the pore closure. This is estimation is 
shared by Kortüm et al. as they suggest this likely causes a steric hindrance and 
result into a function-altering mechanism of disease (Figure 3C).191 Furthermore, 
previous studies have concluded that missense DNMs in ion-channel genes are 
likely to result in DDs: The location and type of missense mutations in these 
channel genes may result in different phenotypes depending on whether they 
alter the function or disrupt the entire structure of the proteins.192,193 Additionally, 
we previously found this protein domain family to be significantly enriched with 
missense DNMs in genes that are associated to DDs.179 Considering these analyses, 
we argue that missense mutations at the identified hotspots are likely deleterious 
to the domain function. 
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Figure 3. Structural changes due to missense DNMs in DD-associated genes for each hotspot. 
A. Homology model of the KCNQ3 complex (Source PDB ID: 5VMS) with missense DNM p.R227Q 
marked as a green to red change. The KCNQ3 complex is a tetramer constructed from four copies 
of the KCNQ3 monomer. All monomers are marked in different color shades. This DNM is located 
at identified hotspot p.96. The wild-type Arginine residue is part of the voltage-sensing helix and 
changed into a Glutamine. This change causes it to lose the positive charged that was previously 
found to cause a function-altering mechanism of disease.189
B. Homology model of CACNA1A (Source PDB ID: 6JPB) with missense DNM p.R1663Q marked as 
a green to red change. This DNM is located at identified hotspot p.102. The wild-type Arginine 
residue is part of the voltage-sensing helix and changed into a Glutamine. This change causes it 
to lose the positive charged that was previously found to cause a function-altering mechanism of 
disease.190
C. Homology model of the KCNH1 complex (Source PDB ID: 5K7L) with missense DNM p.G496R 
marked as a green to red change. The KCNH1 complex is a tetramer constructed from four copies 
of the KCNH1 monomer. All monomers are marked in different color shades. This DNM is located 
at identified hotspot p.231. The wild-type Glycine residue is near the pore-closing region and 
changed into a much larger Arginine. This may impact pore closure and is previously reported to 
result into a function altering mechanism of disease.191
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We focused on 6 mutations in the 6 genes that had no developmental disorder 
association: TRPM5, TPCN2, TPCN1, KCNH5, KCNG1, and CACNA1B. We conducted 
a literature review for each of the 6 genes. The CACNA1B gene was recently 
established as a DD-associated gene on the basis of nonsense DNM enrichment.194 
For KCNH5 a DNM, identical to the one in our analysis, was described as a variant of 
unknown significance (VUS) in a patient with epileptic encephalopathy.195 Protein 
structural analysis revealed that this variant weakens ionic interactions between 
other neighbouring negatively charged residues that destabilizes channel resting 
and activation states of the ion channel.196 The variant was not from the patient 
included in the Kaplanis et al. study, meaning there are two patients with similar 
phenotypes and the same potentially causative variant. The patient from the 
Kaplanis et al. study is part of a cohort in an upcoming study which proposes KCNH5 
as a novel candidate gene for DD-association based on more likely pathogenic 
variants identified in this gene (personal communication with Heather Mefford 
and Erin Torti 25th of September & 6th of October 2020). Both TPCN1 and TPCN2 
have no DD-association at the moment, however, they are both part of the mTOR 
complex. Genes that are part of this complex have previously been associated 
to DDs.197 Specifically, variations in genes related to mTOR are associated to 
intracranial volume and intellectual disability.198 In-house phenotypic data for 
the patient with the missense DNM in TPCN1 (p.265R>Q) at hotspot p.96 fits this 
hypothesis as this patient has macrocephaly and severe ASD. To the best of our 
knowledge, no current literature points to a DD-association for KCNG1 or TRPM5. 
Finally, we classified each variant according to the ACMG guidelines (Table 1, 
Supp. Table 4). The DNMs in KCNH5 and CACNA1B are class 5 (Pathogenic) and the 
other DNMs as class 4 (Likely Pathogenic). A detailed description of the missense 
DNMs in these six candidate genes are described in Table 1.
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Variant Gene Literature 
evidence for likely 
DD-association
gnomAD AF / 
SIFT / Polyphen-2 










Unknown 1,20E-02 // 
Deleterious (0) // 
Probably dama-










Part of the mTOR 
complex 197
- // Deleterious 
(0.02) // Probably 
damaging (0.965) 











Part of the mTOR 
complex 197
7.97e-06 // Tolera-
ted (0.1) // Possibly 
damaging (0.903) 












lated patient with 
epileptic encephal-
opathy 195
- // Deleterious (0) 
// Probably dama-
ging (0.999) // 1.93 










Unknown - // Deleterious 
(0) // Probably 
damaging (1) // 










Nonsense DNMs in 
CACNA1B lead to a 
neurodevelopmental 
disorder with seizu-




Deleterious (0) // 
Probably dama-
ging (0.999) // 1.32 




Table 1. Overview of the variants found at the hotspots that are located in genes that are not in 
the consensus and discordant gene lists of Kaplanis et al.179 We used the Ensembl Variant Effect 
Predictor (VEP)199 to annotate gnomAD allele frequency (AF)51, SIFT200, Polyphen-228, MPC11, and the 
CADD_Phred29. MetaDome53 tolerance indication based on regional dN/dS was obtained manually. ACGM201 classification was obtained through variant curation by a laboratory specialist.




Robustly predicting the pathogenicity of mutations is fundamental to improve 
patient diagnostics and to the advancement of our understanding of the biology 
underlying disease. Previously, the re-occurrence of missense mutations at 
identical homologous domain positions has been used to successfully implicate 
function and separate driver from passenger mutations in cancer.61,182,186,202–204 
The mCluster183 scoring and the DS-Score186 approaches were both developed 
specifically to this purpose, and, we based the MDHS p-value (Equation 1) on 
these previous methods. The MDHS p-value identified three hotspots enriched 
with missense DNMs in patients with DDs, and, all hotspots are located in the 
Ion Transport protein domain family (PF00520). In contrast to computing DNM 
enrichment per gene, we computed enrichment of DNMs at equivalent protein 
domain positions. This way we identified functionally important mutational 
hotspots. We have shown that the missense mutations at these hotspots disrupt 
domain function in the 3D protein structure. Six of the 25 genes that had missense 
DNMs at these hotspots had no previous diagnostic DD-association. Although 
this does not without a doubt confirm that these DNMs are the cause of disease 
for these six novel candidates, it does show that these genes are worth extra 
consideration for further functional DD-association studies. To that extent, of 
the six novel candidate genes we found, KCNH5 and CACNA1B have been recently 
associated to DDs. TPCN1 and TPCN2 are likely candidates as they are part of the 
mTOR complex. For KCNG1 we could not find anything in particular pointing to DD-
association. We evaluated any other DNMs identified in these patients in order to 
exclude an existing diagnosis (Supp. Data S8). The patient with a missense DNMs 
at the hotspot in TRPM5 also has DNMs in established DD-associated genes SLC9A1 
and ADNP, making TRPM5 a less likely candidate gene for DD-association. None of 
the other 5 patients have DNMs in a gene with a currently known DD-association.
In line with previous finding that missense clusters indicate functional 
importance,104,119,205,206 here we identified DNM hotspots in protein domains of 
likely functional importance. Using our MDHS p-value we found 32 missense DNM 
hotspots based on 15,322 DNMs. After filtering these 32 hotspots with the criteria 
that the DNMs driving enrichment should span at least two different gene-codons, 
23 hotspots remained. We cannot exclude that some of these 23 hotspots may have 
been identified due to gene-based DNM hotspots. However, the three hotspots 
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that we analysed extensively were also part of these 23 hotspots, indicating that 
maybe more of the 23 hotspots are due to domain-based enrichment. The 245 
missense DNMs that led to the identification of the 23 hotspots resulted from 67 
genes. Nineteen of these 67 genes were not associated to DDs in the Kaplanis et al. 
study. In our extensive analysis we discussed six of these nineteen genes. Of these 
six we proposed five as likely DD-associations. 
Methods that make use of protein domain architecture to aggregate variants will 
increase in precision with the influx of larger datasets.93 Therefore, in the future 
more discoveries of protein domain missense DNM hotspots in DD patients is 
possible if cohort size increases, and, this will further drive candidate association 
of genes to DDs and understanding of molecular mechanisms of DNMs on protein 
structure and function.




All supplementary information can be found online
https://wiel.science/publications/domain_dnm_hotspots

“Pass on what you have learned. Strength. Mastery. But weakness, folly, failure 
also. Yes, failure most of all. The greatest teacher, failure is.”
–
Yoda in Star Wars Episode VIII – The Last Jedi (2017)  





Data integration is important for DNA variant 
interpretation
Human DNA is complex and contains much more information than just the 
nucleotide sequence. For example, the DNA has a particular 3-dimensional 
structure which is folded around histones at specific locations and encodes for 
proteins, furthermore parts of these proteins can contain protein domain regions 
with a particular structure and function. Representing DNA as just a sequence 
of letters allows for both human and computer readability at the cost of losing 
information, this can be recovered by adding it as metadata and annotations. 
Integration of many layers of information is challenging, but crucial for the 
interpretation of genetic variation. 
I have integrated genome data with protein domain sequences in so-called meta-
domains, which have been mapped on 3D structures. The concept of meta-
domains, that allows for transfer of information between equivalent residues in 
different proteins (Chapter 2),93 has been implemented in MetaDome (Chapter 
3).53 MetaDome was instrumental in a series of developmental disorder studies 
that contributed to the identification of 36 novel candidate gene associations 
(Chapter 4, 5, and 6).104,179 Mapping the mutations on 3-dimensional protein 
structures revealed the likely disease-mechanism for eight of these candidate 
genes (Chapter 4 and 6). A single variant in a meta-domain mutation hotspot 
helped identify six of these 36 candidate disease-genes (Chapter 6).
I will discuss how meta-domains have helped increase our understanding of 
genetic variation, and I will discuss the limitations of meta-domains and their 
potential future use.
The completeness of genetic variation
Reaching saturation of tolerated genetic variation
In 1943, mathematician Abraham Wald calculated which parts of B-17 bomber 
planes needed extra armour in order to increase their survivability. He aggregated 
bullet hole location data from B-17s that returned from missions. He visualised 
this on a schematic representation of a B-17 (Figure 1A). One might intuitively 




adding extra armour to the areas that are rarely damaged. This indeed increased 
survivability because airplanes with damage in these areas never returned.207,208 
This example of ‘survivorship bias’208 resembles the genetic tolerance that was 
discussed in the Introduction. In Chapter 2 we showed that genetic tolerance of 
regions is preserved across domain homologues. We illustrated that this principle, 
similar to Wald’s case, can be used to predict regions that are essential, and thus 
predict likely deleteriousness of novel genetic variants. It has been shown that 
novel missense mutations observed in intolerant regions tend to be disease-
causing too.11,209–211
A.
Figure 1. A. Example of ‘survivorship bias’ based on a schematic representation of a B-17 airplane. 
The red dots indicate bullet holes found on B-17s that returned after missions. The green dotted 
ellipses indicate areas where almost no bullet hole was found on surviving B-17s. (Airplane image 





Figure 1. B. Example of the protein kinase domain (PF00069) in the CDK13 protein structure. 
The green blobs are positions that are consistently enriched in meta-domain based on ExAC50 
missense variants from 353 homologues. De novo mutations known to cause a developmental 
disorder are displayed as dark red blobs. These red blobs are located in the region depleted 
of aggregated population-based variation. (Protein image was created using YASARA14 modeling 
software based on the PDB structure 5EFQ212).
It is estimated that saturation of tolerated variation will require population 
studies in the hundreds of millions of individuals.51 The publicly available genetic 
data resulting from population-based sequencing studies increased from 1,000 
to 141,456 individuals in the past decade.47,50,51,58 The size of population-based 
studies will likely continue to grow in the coming years, but it may take several 
decades before saturation is reached. Additionally, not all variation will be found 
through population sequencing studies alone. For example, only half of all protein 




expected to be heterozygous lethal.51 Sequencing studies of rare variation with 
low propagation chance may help compensate here, for example, large scale 
genetic studies on stillbirth or infertility.213–215
Meta-domains can help to reach saturation of all tolerated genetic variation 
much sooner. Meta-domains can aggregate variation found in regions that cover 
41% of the human genome. For example, we can aggregate missense variants 
encountered in gnomAD over all 353 instances of the Protein Kinase domain 
(PF00069) in the human genome. Then, a pattern of tolerated missense variation 
emerges in the 3D protein structure (Figure 1B). Located inside the intolerant 
region in Figure 1B are confirmed pathogenic missense mutations which indicate 
the intolerant region’s deleteriousness. This example is only an indication of the 
usefulness of data integration to reduce the need for sequencing studies.
The importance of missense variant location and genetic data of 
unknown clinical significance
In contrast to Wald’s situation, in genetics we sometimes do have “bullet hole 
information from the planes that did not survive”: pathogenic mutations in 
patients with a genetic disorder. Distinguishing benign variation from pathogenic 
mutations, even in intolerant regions, remains challenging. Combining novel 
variants from patients with a suspected genetic disorder can help identify commonly 
affected regions in a gene, protein, or, over protein domain homologue. Data 
such as the growing collection of DNMs from patient cohorts with undiagnosed 
DDs59,109,114,120,123,127,128,179,216–223 have proven especially helpful: sequence-based 
clusters of missense variants of unknown clinical significance can predict 
dominant vs recessive inheritance patterns,116 distinguish haploinsufficiency and 
non-haploinsufficiency disease mechanisms (Chapter 4),104 and identify positions 
where variation may trigger a function-altering mechanism of disease (Chapter 
6). All in all, clustering of variants of uncertain significance is likely to indicate 
functional importance.104,119,205,206,224 Discovery of the location of disease-causing 
missense variants uncovers a great deal of understanding behind a possible 
disease-mechanism, and perhaps in the future, treatments.
These methods are very powerful but require large datasets. It will therefore be 
crucial to keep forming large collaborations to combine large datasets of missense 
variants with pathogenic, benign, or unknown clinical significance.
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The limitations of meta-domains
The need for high abundance and high quality data for meta-domains
Biological data is inherently noisy and varies in data quality due to a myriad of 
reasons.225 A well understood computer science principal is “Garbage in, Garbage 
out” meaning that the quality of results of any method is dependent on the quality 
of the input data. Meta-domains are no exception to this. In fact, Meta-domains 
are highly dependent on the quality and amount of genetic information that is 
integrated. For example, whereas individuals with a childhood-onset disease were 
excluded from gnomAD, pathogenic variation part of recessive, polygenic, and/
or late-onset genetic disorders is still present in gnomAD.51 Computing tolerance 
based on gnomAD could therefore result in assigning regions as tolerant, whereas 
they are not. For this reason we removed rare variants and variants present in 
HGMD91 or ClinVar54 from our analyses in Chapter 2. On the other hand, a large 
percentage of variants are incorrectly marked as pathogenic in clinically relevant 
databases.85–87 One of the reasons for this is that most small scale studies cannot 
be successfully replicated.226 Luckily, these databases are gradually improved in 
both quantity and quality and thereby meta-domains will increase in efficacy too.
Reasoning on variant pathogenicity with meta-domains
Protein domains cover 41% of the human genome sequence.93 Meta-domains can 
utilise the within-human domain homologues to aggregate variant information. 
There are currently 3,334 Pfam-based meta-domains. These meta-domains have 
two, up to hundreds, of domain occurrences throughout the human genome. 
For example, the Protein kinase domain (PF00069) meta-domain in Figure 1B 
has 353 occurrences throughout the human genome.53 The usefulness of variant 
aggregation in meta-domains scales with the number of homologue occurrences. 
Meaning that, for a low number of occurrences, the chance of encountering 
multiple variants from different protein domains diminishes. Additionally, the 
chance to observe biological signals from aggregated variation in meta-domains 
becomes smaller. Therefore, the efficacy of meta-domains is dependent on the 
number of homologue occurrences. Still, I would argue that even a single hit 
of a pathogenic variant at an equivalent protein position may be informative 
for evaluating a patient’s candidate missense variant. First of all, homology is 




similar effects on protein stability.40 Because protein domains are evolutionary 
conserved regions, pathogenic missense mutations in human protein domains 
have similar pathogenic effects in yeast.181 Therefore, finding a novel missense 
variant in a meta-domain, which at an equivalent protein domain position leads 
to disease, provides more support for pathogenicity than when encountering 
identical novel variants in two patients.
Meta-domains are constructed on sequence-based protein domain 
identification methods
Protein domains are at the core of the meta-domain concept and therefore the 
quality and completeness of protein domains determine to a large degree the 
meta-domain efficacy. We have built meta-domains upon Pfam41 domain families, 
which are based on multiple sequence alignments of conserved sequences that 
overlap between evolutionary related species. Pfam is one of many protein domain 
identification methods. Typically, protein domain identification methods can be 
categorised into sequence-based and protein structure-based approaches.227 Meta-
domains can aggregate variant information over homologous protein domains, 
and, using a sequence-based approach has major benefits for aggregation. Firstly, 
sequence alignments force residues that are evolutionary conserved to be ‘aligned’ 
at identical positions. This allows for ease of aggregation from a computational 
perspective while retaining high certainty that these positions are identical from 
an evolutionary perspective. Secondly, sequence information is much more 
prevalent than protein structure information (Figure 2). Thus, Pfam-based 
meta-domains cover a large part of the human genome but at the cost of losing 
molecular structure information, however, highly related sequence homologues 
in general share the same protein structure.227 In addition, structural information 
can be annotated to sequence-based protein domains. Recently, Pfam expanded 
annotation of PDB structures and structural models for 88% of the Pfam domain 
families.228 This suggests that the loss of molecular structure information may 
soon be less of an issue for sequence-based meta-domains.
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Figure 2.   
Growth of protein structural coverage of the human genome based on sequence. This coverage 
does not take into account the 44% of protein sequences without a rigid structure, also called 
the dark proteome229 (Image adapted from the SWISS-MODEL Repository and is licensed under 
Creative Commons CC BY-SA 4.0 – swissmodel.expasy.org).230
The future of meta-domains
Sequence-based protein structure prediction
So, why focus on structure-based methods for meta-domains at all? Structure is 
more conserved than sequence,37,44 which is why structure-based domain detection 
is more sensitive than sequence-based detection. It can identify homologues 




methods.227 Meta-domains that are built on structure-based domain identification 
methods will therefore add to the overall coverage of the genome. A meta-
domain-like approach using CATH187,231 structure-based protein domain families 
was recently proposed by Ashford et al. (2019). This approach was suggested to 
be complementary to meta-domains.182 However, the major limiting factor with a 
pure structure-based approach remains the structural coverage of sequences. As 
of 2008 the amount of unique structural folds have stagnated in the Protein Data 
Bank.227 The growth of structural protein coverage of sequences so far has mostly 
happened due to the betterment of structure determination and 3D homology 
modelling methods (Figure 2).230
A full structural coverage of the human genome sequence will likely never be 
reached. In fact, 44% of the total human genome protein-coding sequence 
consists of (partial) natively unfolded proteins called the dark proteome229 (e.g. 
proteins that do not conform to a rigid structure). Nevertheless, there is still much 
to improve (Figure 2). Accurate prediction of protein structure based on sequence 
alone has been an unsolved challenge since the 1980s. Interestingly, however, 
it may have been solved only very recently with AlphaFold2’s participation in 
the annual Critical Assessment of Structure Prediction (CASP) challenge.232 The 
preliminary results of this novel computational approach show a tremendous leap 
forward compared to previous years. Two-thirds of structure predictions resulting 
from AlphaFold2 are indistinguishable from experimentally determined protein 
structures. A full description of AlphaFold2 has yet to be released but it builds 
further on the previous AlphaFold approach.233 The impact of AlphaFold2 will likely 
lead to a large part of protein-coding genes to have a predicted protein structure. 
This will have a major effect on protein domain identification methods from at 
least two perspectives. Firstly, sequence-based domain methods are more likely 
to have a structure assigned. This increases the potential to analyse the molecular 
effects of mutations in these protein domains. Secondly, with more (predicted) 
structure, structure-based domain methods might uncover protein domains for 
which previously the structural coverage was too limited. These sequence-based 
and structure-based perspectives will both be beneficial for meta-domains; the 
catalogue of homologous protein domains will grow and so will the potential to 
analyse molecular effects of mutations in protein domains.
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Population-based variant allele frequency can complement 
evolutionary conservation
Evolutionary conservation is a strong predictor of pathogenicity and heavily used 
in pathogenicity predictors such as Polyphen-228 and CADD29. These predictors 
perform well, but leave room for improvement especially within a clinical 
context.55–57 In Chapter 2 we show that 54% of the aggregated protein domain 
positions with one or more disease-causing missense variants were found to 
be evolutionary variable. If we assume that most disease-causing variants are 
correctly marked as pathogenic in the clinically relevant databases, then this 
could be an indication that evolutionary conservation could be complemented 
by population-based data. One way meta-domains can complement evolutionary 
conservation is by the inclusion of the population frequency of variants. For 
example, in most of our analyses including the display in the MetaDome web 
server, we only use the aggregated missense counts. Instead, the frequency of 
missense variants encountered in general population could be used. This way, 
MetaDome could represent amino acid frequency across homologous domain 
positions as a complement to evolutionary conservation scores.
The validation of the full mutational spectra in meta-domains
To quote George Box (1978) - “All models are wrong but some are useful”, which also 
applies to meta-domains. Therefore, validation of models remains essential. In 
a study by Peterson et al. (2013) yeast was used as a model organism to validate 
deleterious effects of recurring pathogenic missense mutations at homologous 
human protein domain positions.181 This study suggests that pathogenic missense 
mutations in protein domains have similar deleterious effects across species. 
Furthermore, this opens the door to use the vast amount of clinical data from 
the human genome to predict deleteriousness in other organisms. To achieve 
validation on a much larger scale in the future, we may be able to combine data 
from deep mutational scanning with meta-domains. Deep mutational scanning is 
a high-throughput method that allows for editing and analysing the effect of every 
single nucleotide variant change over a stretch of nucleotides in a massively parallel 
manner.234–237 Already, data resulting from deep mutational scanning projects 
are empowering protein structure determination, co-variation and variant effect 
prediction.238–240 However; deep mutational scanning has two major limitations. 




mutational effects there needs to be a clear functional readout. To date, the 
protein coding region of BRCA1 is the largest stretch of nucleotides that has been 
tested with deep mutational scanning.241 In this study by Findlay et al. (2018), each 
possible variant in BRCA1 was tested for its functional effect on homology-directed 
DNA repair, a mechanism that is necessary for tumour suppression. Meta-domains 
are a perfect candidate for deep mutational scanning projects. First of all, protein 
domains cover small parts of a protein. Secondly, a large proportion of protein 
domains have a specific function that may be very suitable for a functional read-
out. Thirdly, performing deep mutational scanning on a single protein domain has 
implications for all homologous occurrences. If we reason from the findings of the 
yeast study of Peterson et. al. (2013) these implications may be cross-species.181 
I therefore believe that deep mutational scanning is the next step to filter out 
domain-specific from protein-specific mutational effects. 
The future of meta-domains without reinventing “de Wiel”
In this thesis we have discussed how to evaluate variant pathogenicity using the 
meta-domain concept. We have shown how meta-domains can lead to a deeper 
understanding of disease-mechanisms by capturing signals from ‘noisy’ clinical data 
of unknown significance. Previous studies in cancer genetics have utilised reasoning 
and concepts that bear some resemblance to meta-domains.61,180–183,203,204,242–244 These 
studies, to me, are an indication that with the growth of genomic information, 
methods that were originally intended for different purposes may become more 
and more relevant. 
Reuse of previously proved concepts also underlies the design of MetaDome. The 
goal for constructing the MetaDome web server was to make the abstract concept 
of meta-domains available in a user-friendly manner. My computer science 
background allowed me to set up MetaDome in accordance to up-to-date standard 
practice. Firstly, the code is completely documented and publicly available as open 
source on a code repository. Secondly, MetaDome is ‘containerized’, meaning 
that anyone willing can run MetaDome on their own personal computer set-
up identically to the actual server. The containerization will ensure the identical 
environment, regardless of the host machine’s operating system or software 
versions. Containerization is especially helpful in scientific projects. For example, 
it ensures that referees are able to run the identical software during peer review. 
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Furthermore, containerization ensures indefinitely operational software. This 
last part often proves to be a problem in scientific labs where it is common that 
developers of the software migrate to different labs together with their expertise. 
This expertise is especially missed when hardware or software dependencies are 
upgraded that may result in non-functional software. This is not a problem for 
containerized software. Lastly, incorporating usage tracking in a web server helps 
in understanding how much it is used more than citation count would. I therefore 
believe that usage statistics should be part of grant applications that are specific 
to the continuation of scientific software projects. MetaDome has now (March 
2021) been used by ~5,100 individuals from 80 countries since the initial release 
(November 2018). MetaDome is still steadily growing in monthly users with 460 
users in the last month. The growth of users for MetaDome is a testament to 
its success, and, for the need of providing easily-accessible and user-friendly 
ways to handle the increasingly complex concepts that arise from the growth of 
genomic data. I believe these are lessons long learned in computer science at that 
computational biologists do not need reinvent the wheel.
In this discussion I have explored the potential applications of meta-domains 
that are outside of the scope of this thesis. I have examined the limitations to the 
concept of meta-domains, and, how they may be resolved. Lastly, I have provided 
a glimpse into the potential future of meta-domains. These future perspectives 
may lead to more accurate prediction and better understanding of mutational 
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Ethical compliance, consent, and FAIR patient data
Work in this thesis is based on the results from human studies. These studies 
were conducted in accordance with the principles of the Declaration of Helsinki. 
All families involved in these human studies gave informed consent. The human 
studies in this thesis were approved and conducted in accordance to the guidelines 
set forth by:
• The medical and ethical review board Committee on Research Involving 
Human Subjects Region Arnhem Nijmegen (2011/188). 
• The UK Research Ethics Committee (10/H0305/83 granted by the Cambridge 
South Research Ethics Committee, and GEN/284/12 granted by the Republic 
of Ireland Research Ethics Committee).
• The Western Institutional Review Board, Puyallup, WA (WIRB 20162523).
All analysed data, resulting from these human studies, has been included in 
the published articles. Any additional files are available from the associated 
corresponding authors on request. Raw sample material and identifiable clinical 
information were not part of the publications. Sequence and variant-level data and 
phenotypic data for the DDD study data are available from the European Genome-
phenome Archive (EGA) with study ID EGAS00001000775. The Radboudumc 
sequence and variant-level data are stored on the Radboudumc Human Genetics 
department server and cannot be made available through the EGA owing to the 
nature of consent for clinical testing. In accordance to ‘Wet op de geneeskundige 
behandelingsovereenkomst’ (WGBO), Radboudumc patient data will be kept 
for fifteen years after publication. To access this data, please contact Christian 
Gilissen with a request. Data sharing will be dependent on patient consent, 
diagnostic status of the patient, the type of request and the potential benefit to 
the patient. GeneDx data cannot be made available through the EGA owing to 
the nature of consent for clinical testing. GeneDx-referred patients are consented 
for aggregate, deidentified research and subject to US HIPAA privacy protection. 
As such, GeneDX is not able to share patient-level BAM or VCF data, which are 
potentially identifiable without a HIPAA Business Associate Agreement. Access to 
the deidentified aggregate data used in this analysis is available upon request to 
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GeneDx. Clinically interpreted variants and associated phenotypes from the DDD 
study are available through DECIPHER. Clinically interpreted variants from RUMC 
are available from the Dutch national initiative for sharing variant classifications 
(VKGL) as well as LOVD, where they are listed with ‘VKGL-NL_Nijmegen’ as the 
owner. Clinically interpreted variants from GeneDx are deposited in ClinVar under 
accession number 26957.
Usage of public resources
The analyses in Chapter 2, 3, 4, and, 6 were performed on scientifically published 
public datasets and resources. Citations, version numbers, and, identifiers were 
used to link back to these resources. See the methods and material section of 
each article for step-by-step ways to reproduce the results. See the Web links & 
resources and Availability and identifiability of supporting data for further 
details.
Availability and identifiability of supporting data
All supporting data of work in this thesis have been (or will be) made accessible 
upon publication of the corresponding articles. Each element in the supporting 
data has been assigned an identifier:
• Data resulting from patient material samples are provided with a ‘sample 
identifier’. This identifier, publicly, cannot directly be linked back to 
identifiable information of a patient. Internally, at Radboudumc, DDD, and 
GeneDX, these links may be made by the appropriate clinicians. If such 
information is required, it may be obtained via the associated corresponding 
authors of the studies.
• All genes references in were marked by GENCODE and/or RefSeq IDs.
• All disease related phenotypes or genotypes had associated OMIM IDs.
• Any references to variants had a corresponding ClinVar, HGMD, ExAC, or 
gnomAD IDs.
• Every protein structure has an associated PDB ID. The template structure’s 
PDB ID was noted if it was a homology modelled structure.
• Protein domains have a Pfam and/or Interpro ID.




All Source code used for Chapter 2 was made available with release of MetaDome 
in Chapter 3. The code for SpatialClustering in Chapter 4, and DeNovoWest and 
Phenopy from Chapter 5 are available on Github. Source code for the analyses in 
unpublished Chapter 6 will be made available via GitHub upon publication. See 
Code repositories for links to the repositories and a listing of Tools, Frameworks 
and Programming languages used.
Code repositories
DeNovoWest:   https://github.com/queenjobo/DeNovoWEST
MetaDome:   https://github.com/cmbi/metadome
Phenopy    https://github.com/GeneDx/phenopy
SpatialClustering:  https://github.com/laurensvdwiel/SpatialClustering
Tools, Frameworks and Programming languages
Biopython:   https://biopython.org/
BULMA:    https://bulma.io/
Celery:    http://www.celeryproject.org/
Docker:    https://www.docker.com/
D3.js:    https://d3js.org/
Flask:    https://palletsprojects.com/p/flask/
Jupyter:    https://jupyter.org/
PostgreSQL:   https://www.postgresql.org/
Python:    https://www.python.org/
RabbitMQ:   \https://www.rabbitmq.com/
Redis:    https://redis.io/
Web links & resources
CADD:    https://cadd.gs.washington.edu/
ClinVar:    https://www.ncbi.nlm.nih.gov/clinvar/
CMBI PDB facilities:  http://swift.cmbi.ru.nl/gv/facilities/
DECIPHER  https://decipher.sanger.ac.uk
Denovo-db:   https://denovo-db.gs.washington.edu/
DDG2P:    https://www.ebi.ac.uk/gene2phenotype/downloads
DDD:    https://decipher.sanger.ac.uk/ddd
EGA   https://www.ebi.ac.uk/ega/
ExAC:    https://exac.broadinstitute.org/
GENCODE:   https://www.gencodegenes.org/
gnomAD:   https://gnomad.broadinstitute.org/
HGMD:    http://www.hgmd.cf.ac.uk/
HMMER:    http://hmmer.org/
HOPE:    http://www.cmbi.ru.nl/hope/
InterPro:    https://www.ebi.ac.uk/interpro/
Lift Over tool:   https://genome.ucsc.edu/cgi-bin/hgLiftOver
LOVD   https://databases.lovd.nl/shared/variants
MetaDome:   https://stuart.radboudumc.nl/metadome/
MRS:    https://mrs.cmbi.umcn.nl/
NHLBI ESP:   https://evs.gs.washington.edu/
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OMIM:    https://www.omim.org/
Pfam:    https://pfam.xfam.org/
RCSB PDB:   http://www.rcsb.org
RefSeq   https://www.ncbi.nlm.nih.gov/refseq/
RVIS:    http://genic-intolerance.org/
subRVIS:    http://www.subrvis.org/
UniProtKB/Swiss-Prot:  https://www.uniprot.org/
VKGL   https://www.vkgl.nl/nl/diagnostiek/vkgl-datashare-database
wwPDB:    www.wwpdb.org






About 2-5% of all children are born with severe developmental disorders (DDs) 
and about half of these cases have a genetic cause. Despite that hundreds of DD-
associated genes have been identified, the genetic cause for two-third of these 
patients remains undiagnosed. A genetic diagnosis helps families in many ways. 
They can join support networks, get information about possible treatments, and 
they learn about the risks for having further children. DDs are often the result 
of de novo mutations (DNMs) that are thus not inherited from the parents. Every 
individual has about 1-2 de novo mutations in the protein-coding regions of the 
genome. This low number of DNMs makes it hard to gather enough data for 
proper statistical treatment. Large-scale projects have been performed over 
the past decade to gather data on a world-wide scale. This has allowed for the 
association of a series of DDs to genes; often by finding a larger number of DNMs 
in one gene than expected in the patient cohort.
This thesis integrates human genome data with 3D protein structures with a focus 
on structure domains. This integration allows for the detection of disease-causing 
effects of mutations and has contributed to the identification of 36 candidate 
disease-gene associations for DDs. These newly associated genes directly enabled 
diagnosis for 500 families included in the studies and many more to follow world-
wide. 
The meta-domain framework and the MetaDome web server
1-2% of the human DNA codes for proteins, of these proteins 42% are formed 
by recurring protein domains. Domains are small parts of a protein with specific 
structure and function. Often very different proteins share structurally highly 
similar domains that are homologs. 
In Chapter 2 we introduce meta-domains as the alignment of the proteome on 
human Pfam domains. These meta-domains are annotated with data extracted 
from pathogenic and population-based variation databases, genomic locations, 
evolutionary conservation, etc. Meta-domains allow for transfer of information 
between equivalent residues in different proteins. In Chapter 3 we describe the 
MetaDome web server that uses this concept to support the analysis of genetic 
variants of unknown clinical significance. MetaDome makes the abstract concept of 





Identification of candidate developmental disorder genes and 
disease mechanisms
In Chapter 4 we used spatial clustering on publicly available DNM DD-patient 
data to identify missense DNM clusters in fifteen genes, three of which were 
not previously associated with DD. Analysis of these clusters in the protein 3D 
structure suggested a Non-Haploinsufficiency disease-mechanism.
In Chapter 5 we describe how a unique international collaboration between the 
Radboudumc, GeneDX, and the Wellcome Sanger Institute shared healthcare data 
of 31,058 parent-offspring trios of patients with DDs. In the resulting article in 
Nature we describe a series of innovations that were only possible thanks to the 
large size of this dataset. 285 DD-associations to genes could be made, of which 
28 were previously unknown. We estimate that for at least ~1,000 genes a DD-
association is still to be discovered, indicating how much work remains. This article 
will serve as a reference point to understand the genomic architecture of DNMs 
and DDs for years to come.
In Chapter 5 we also observed that more than two-third of all missense DNMs 
in DD-associated genes are found in domains, of which ion transport domains, 
ligand-gated ion channels, protein kinase domains, and kinesin motor domains 
are most enriched. In Chapter 4 we concluded that disease associated DNMs tend 
to cluster in the 3D protein structure, and in Chapter 6 we invert this reasoning 
and use the clustering of DNMs in 3D protein structures as an indication of their 
disease association. After removing the genetic redundancy from the 45,221 
DNMs from Chapter 5, MetaDome found three missense DNM hotspots in the 
ion transport domain. These were found in 25 genes, 19 of which were already 
DD-associated. Human analyses of the 3D protein structures suggested a similar 
functional role for the native residue at each hotspot, suggesting that the DNMs 
in the six novel genes are deleterious too. Chapter 6 thus shows that a novel way 





Ongeveer 2-5% van alle kinderen wordt geboren met een ernstige 
ontwikkelingsstoornis (OS) en ongeveer de helft van deze stoornissen heeft een 
genetische oorzaak. Ondanks dat er honderden OS-geassocieerde genen bekend 
zijn, blijft de genetische oorzaak onbekend voor tweederde van de patiënten. Een 
genetische diagnose helpt gezinnen op veel manieren. Ze kunnen lid worden van 
ondersteunende netwerken, informatie krijgen over mogelijke behandelingen 
en ze leren over de risico’s van het krijgen van meer kinderen. OS zijn vaak het 
resultaat van de novo mutaties (DNMs) die dus niet van de ouders worden geërfd. 
Elk individu heeft ongeveer 1-2 de novo mutaties in de eiwit coderende regio’s 
van het genoom. Dit lage aantal DNMs maakt het moeilijk om voldoende data te 
verzamelen voor een statistische verband legging. Er zijn het afgelopen decennium 
grootschalige projecten uitgevoerd om gegevens van patiënten met een OS op 
wereldwijde schaal te verzamelen. Door in een patiënten cohort een groter aantal 
DNMs in één gen te vinden dan verwacht maakt het mogelijk om dat gen met OS 
te associëren.
Dit proefschrift integreert menselijke genoom gegevens met 3D-eiwitstructuren 
met een focus op structuur domeinen. Deze integratie maakt de detectie van 
ziekteverwekkende effecten van mutaties mogelijk en heeft bijgedragen tot 
het ontdekken van 36 kandidaat-ziektegen associaties voor OS. Deze nieuw 
geassocieerde genen maakten de diagnose direct mogelijk voor 500 families die 
deel uit maakte van de studies en er zullen er wereldwijd nog veel meer volgen.
Het meta-domein framework en de MetaDome webserver
1-2% van het menselijk DNA codeert voor eiwitten. Van deze eiwitten wordt 42% 
gevormd door eiwitdomeinen. Domeinen zijn kleine onderdelen van een eiwit met 
een specifieke structuur en functie. Vaak kun je over verschillende eiwitten een 
vergelijkbaar structureel domein terugvinden die homoloog zijn.
In Hoofdstuk 2 introduceren we meta-domeinen als een framework die 
samenvoeging van vergelijkbare menselijke Pfam-domeinen mogelijk maakt. Deze 
meta-domeinen worden geannoteerd met: gegevens uit pathogene en algemene-
populatie variatie databases, locaties op het genoom, evolutionaire conservering, 




residuen in verschillende eiwitten mogelijk. In Hoofdstuk 3 presenteren we de 
MetaDome webserver die dit concept gebruikt om de analyse te ondersteunen van 
genetische varianten met onbekende klinische significantie. MetaDome maakt het 
abstracte concept van meta-domeinen algemeen beschikbaar voor onder andere 
wetenschappers met een beperkte bioinformatica-expertise.
Ontdekking van nieuwe kandidaat ziektegenen voor 
ontwikkelingsstoornissen en de ziektemechanismen daarvan
In Hoofdstuk 4 hebben we ‘spatial clustering’ gebruikt op de DNMs uit publiekelijk 
beschikbare OS-patiëntgegevens om clusters van missense DNMs in vijftien 
genen te identificeren. Drie van deze genen waren niet eerder geassocieerd 
met OS. Analyse van deze clusters in de 3D-eiwitstructuur suggereerde een 
ziektemechanisme van niet-haploinsufficiëntie.
In Hoofdstuk 5 beschrijven we hoe een unieke internationale samenwerking 
tussen het Radboudumc, GeneDX en het Wellcome Sanger Institute leidde tot 
het gezamenlijk combineren van DNMs van 31.058 patiënten met een OS. In het 
resulterende artikel in Nature beschrijven we een reeks innovaties die alleen 
mogelijk waren dankzij de grote omvang van deze dataset. Er konden 285 OS-
associaties met genen gemaakt worden, waarvan er 28 voorheen nog niet waren 
ontdekt. We schatten dat voor minstens ~1.000 genen er nog een OS-associatie 
ontbreekt en dat geeft aan hoeveel werk er nog ligt. Dit artikel zal dienen als een 
referentiepunt om de genomische architectuur van DNMs en OS in de komende 
jaren beter te begrijpen.
In Hoofdstuk 5 hebben we ook waargenomen dat meer dan tweederde van alle 
missense DNMs in OS-geassocieerde genen worden gevonden in eiwitdomeinen, 
waarvan ionentransport domeinen, ligand-geactiveerde ionkanalen, proteïne 
kinase domeinen en kinesine-motor domeinen het meest verrijkt zijn. In Hoofdstuk 
4 concludeerden we dat met ziekte geassocieerde DNMs de neiging hebben om 
te clusteren in de 3D-eiwitstructuur, en in Hoofdstuk 6 keren we deze redenering 
om en gebruiken we de clustering van DNMs in 3D-eiwitstructuren als een indicatie 
van hun ziekteassociatie. Na het verwijderen van de genetische redundantie van 
de 45.221 DNMs uit Hoofdstuk 5, vond MetaDome drie missense DNM-hotspots 
in het ionentransport domein. Deze werden gevonden in 25 genen, waarvan er 
al 19 een OS-associatie hadden. Menselijke analyses van de 3D-eiwitstructuren 
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suggereerden een vergelijkbare functionele rol voor het originele residu op elke 
hotspot, wat vervolgens suggereert dat de DNMs in de zes nieuwe genen ook 
schadelijk zijn. Hiermee laten we dus in Hoofdstuk 6 zien dat een nieuwe manier 
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without you will never be the same. Maartje, you set the office rule: ‘always go 
together with roomies for a coffee’. I always tried to follow this rule well after 
we switched office. As bioinformaticians, the joint ‘getting coffee’ often was the 
social interaction we didn’t realize we needed. Dimitra, you always brightened 
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up my day with clever remarks and Greek philosophy. Stéphanie, our very open 
discussions changed my perspective and made me so much more ‘woke’. Thank 
you for acknowledging my blunt questions with your well thought-out answers. I 
have come to know you as an intellectual kind friend of many depths and one of 
the most inclusive of colleagues. Juliet, when you started we were talking a lot 
about our potential postdoc trajectories. I stuck around a bit longer before actually 
taking off. Luckily this made me experience how you coach people. I am sure you 
will make a great PI one day. Brechtje, you always had a captivating story ready 
and were always available for a chat. I liked how you always aimed and succeeded 
in keeping everyone’s spirits up. Simone, you joined the room and thereby 
increased our Aloe vera population by 400%. I am sure the added oxygen had a 
positive effect on all of us. We had lots of coffees together that was often joined 
by a talk on both serious and mundane struggles. I love the way you are artistically 
creative and I hope you will continue to practice your arts. Erdi, your enthusiasm 
for many obscure board games that I never heard about before sparked over to 
me. I can’t wait till we have another board game night together. Suus! Our in-
office senior scientist! You were often very busy, but somehow you always found 
time for funny strict Dutch-English translations. Thank you for ant fucking my 
work so often, this thesis wouldn’t be in the same level of quality without it. It was 
unfortunately peanut butter for us when you transitioned to another office. I hope 
you will keep taking good care of Vera. And remember, you will always be welkom! 
Karolis, somehow we found each other in our love for old school hip hop after 
watching Office Space. I particularly enjoyed our cooking sessions. I hope you will 
still have some time for Developing! Developing! Developing! in the future. Wouter, 
you always seemed to have a listening ear ready for a colleague in need, followed 
by a calmly given piece of advice. Burcu, thank you for the fun chats we had and 
for broadening my knowledge on Turkish culture. Kevin, okay you were not really 
a roommate, but we included you as an honorary member of the GINOMICS. Even 
though you were only in Nijmegen for a short time, you fit in so well and joined 
many nice events. I hope to see you again at a next ASHG or ESHG. Jard, you were 
the silent disc jockey in our room. Even though you were with us for only a year, 
you will forever be highly valued as the co-founding member of GINOMICS.
Judith Grolleman and Manon Oud, our PhDs started around the same time 
and you both brought constant support throughout my PhD academically and 




comfort when work brought me down. And no, I still don’t know the difference 
between a hamster and a guinea pig. Juut! We’ve celebrated many great moments 
together throughout our PhDs. You always seemed to have a bottle of champagne 
stashed away for the next celebration. You have unique social skills to bind and 
excite people towards a common goal. You were the champion of undeserved 
manuscript rejections, and yet you never gave up hope. You radiate kindness, 
trust and intelligence. Manon, you were the most organised PhD student I have 
ever known. Besides that you are kind, intelligent, and always seemed to have 
time for someone else even when you were very busy. It doesn’t surprise me at 
all that you often walked away with well-deserved awards at conferences. You 
never wavered from tough questions. You taught me so many basics of genetics 
and were never too shy to dive in the more advanced topics. Speaking of diving, I 
enjoyed our scuba diving trips and hope you will find more time for exploring the 
watery depths of calmness and serenity in the future.
Working at two departments resulted in double the perks, but also double the 
bureaucracy. Barbara van Kampen, Ineke Zaalmink, Baukje Oosterhof-
Konings, Doménique Nijsten, and Dennis Vissers, I appreciate how you were 
there for me to navigate many of these challenges. Arthur Pistorius, Jon Black, 
and Coos Baakman, I could always count on you for assistance with hardware, 
software or Linux issues that ended up saving me many hours of work. Steven 
Castelein, Marc Pieterse, Rick de Reuver, and Maartje van de Vorst thank you 
for assisting me figure out and navigate the infrastructure of the genetics server. 
This helped me make my first baby-steps in genomics. My productivity was very 
much boosted by having a clean desk. Monique Jacobs and the cleaning team at 
Human Genetics, thank you for making sure this was never a worry on my mind.
I have had the honour of being a supervisor during my PhD. Brecht van den 
Berg, Lucca Derks, Daan Gilissen, Daniel Rademaker, and Wouter-Michiel 
Vierdag thank you for teaching me by coaching you. Daan, your internship laid 
the groundwork design of the characteristic MetaDome tolerance landscape. 
Your place on the publication was well deserved. I have come to know you as a 
hard worker. I am glad to see you have become a colleague now at CMBI. Daniel, 
your internship introduced you to many datasets you ended up working with 
later on in your PhD. I admired how you always knew what everyone was busy 
with or working on. You had a hard time saying no, but this also resulted in many 
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upcoming publications. I am glad you chose to pursue a PhD in the department. 
You have become an essential component of the CMBI by being a true connector 
of people. I am sure you will excel in your PhD.
Perhaps one of the biggest perks of working in academia is the scientific 
conferences that are often located in fantastically vibrant or exotic locations. 
To all of my colleagues that joined me in creating memories that I will forever 
remember with a smile: Chantal Deden, Illja Diets, Sinje Geuer, Christian 
Gilissen, Jakob Goldmann, Judith Grolleman, Alex Hoischen, Simone Kersten, 
Robin van der Lee, Stefan Lelieveld, Britt Mossink, Gaël Nicolas, Manon Oud, 
Margot Reijnders, Roos Schellevis, Lot Snijder-Blok, Marloes Steehouwer, and 
Richarda de Voer. Thank you Jakob for being room buddies at the RIMLS PhD 
retreat 2016 with infinite patience as I lost the room key three times. Room buddy 
Robin at the BioSB 2016. I remember that Jakob and Stefan joined me in the 
monastery of Rolduc dungeon for a beer, where Stefan lost his way but was guided 
by my text message. The ESHG 2017 in Copenhagen was my first experience with 
the ‘Nijmegen house’ tradition. Thank you Christian, Jakob, Judith, Alex, Stefan, 
Gaël, Manon, Margot and Richarda for the spontaneous fun after-conference-
borrels with amazing food in this weird and humongous house that contained 
revealing pictures of the owners and their ‘interesting’ book collection. I will 
forever remember the conference party. The tradition continued in the ASHG 2017 
in Orlando. With the massive apartment, interesting taxi conversations together 
with Han, the need for cooking our own lunches if we didn’t want the fatty foods 
from Denny’s, stubbornly walking to the conference in a country designed for cars, 
and lots and lots of bacon in the morning. Illja, Sinje, Christian, Stefan, Margot, 
Roos, and Lot thank you for the fantastic memories. Sinje and Roos thank you 
for joining me in visiting the Give Kids The World Village. Stefan, Margot, Roos, 
and Lot I can’t wait to go to the theme parks again with you and face the music 
of a mariachi band after being bombarded with impressions all day. Chantal and 
Britt, I enjoyed our pre-conference ESHG 2019 exploration of Gothenburg and 
surroundings. After which we group housed together with Alex, Simone, Manon, 
Lot, Marloes, and Richarda in another ‘Nijmegen house’ villa with a sauna that we 
didn’t dare to use. I remember everyone panicked that I was gone since I had my 
presentation the next day, but after a more thorough search you found I was vast 




Perhaps one of the best pieces of advice I ever got from senior PhD students 
was to join VrijMiBo in the Aesculaaf. I tried my best to live up to this advice and 
passed it on to the next generation of PhD students. We have an exceptionally 
social group of colleagues that always made you feel included. Every Friday 
there would be a core group of colleagues that never seemed to miss a single 
Aesculaaf Friday and every time I met new people too. We would mostly end up 
having grouped dinner afterwards and sometimes even visited another bar. These 
VrijMiBo’s been a de-stressor in the weeks I needed them the most and energised 
me in good weeks. They helped me get to know my colleagues on a more personal 
level. Many collaborations and friendships started here. The going into the city 
afterwards helped me discover food places and parts of Nijmegen that I wouldn’t 
have otherwise. Thank you to everyone that was part of one of these Fridays.
Besides the spontaneously weekly VrijMiBo’s I found much joy and gratitude 
in organizing and hosting social events. At CMBI this started out with our ‘own 
version of the BioSB conference named BYOSB (‘Bring Your Own Speciaal Bier’) 
that had multiple recurrences and later the Dutch Cultural movie night. At genetics 
the honour was bestowed upon Chantal Deden, Suzanne de Bruijn, Jettie van 
Engelen, Stephan Maas, Marc Pauper, and me to organise the yearly day-out 
or DUC2018. Thank you for the pre-, during-, and post- fun of our well-oiled 
organisation team! Hans van Bokhoven, thank you for the excellent idea of going 
deeper than ever before with human genetics. The first Human Genetics Nijmegen 
scuba-diving event was a success and hopefully more will follow. Brooke Latour, 
Alex Hoischen, and me clicked as lovers and explorers of food and drinks and 
sought to share this enthusiasm with others by organising many food and drink 
related events. We have grown to be like-minded friends in the process. Thank 
you Alex for teaching me the meaning of hospitality by exemplifying it in its purest 
form. Thank you to everyone that joined or aided in organising these events.
I was surrounded by many fantastic colleagues during my PhD. Some of you I 
haven’t mentioned by name, so thank you Rocío Acuña-Hidalgo, Peer Arts, 
Galuh Astuti, Sander Bervoets, Jordy Coolen, Rosanne van Deuren, Margo 
Dona, Tom Ederveen, Dei Elurbe, Siebren Faber, Daniel Garza, Josh Gillard, 
Evelien Hurkmans, Charlotte Kaffa, Mubeen Kahn, Gelana Khaveeza, Marije 
Klumpers, Michael Kwint, Ideke Lamers, Anne Niehues, Machteld Oud, Iris 
Te Paske, Gayatri Ramakrishnan, Simon van Reijmersdal, Rick de Reuver, 
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Tabea Riepe, Dimitrijs Rots, Carolien Ruesen, Bart van der Sanden, Ralph 
Slijkerman, Balaji Venkatasubramanian, and Petra de Vries, for joining social 
events, being available for a chat, going out for lunch/dinner together, helping out 
with a tough question, or getting a coffee with an appelflap together. Thank you 
and all other colleagues from Human Genetics and CMBI that helped create an 
atmosphere at work that made lasting memories.
Thank you Ruud van de Wiel, for creating and shaping the cover and thematic 
chapter pictures in this thesis.
To the members of De Waterman scuba diving club, for being a weird bunch 
of awesome people that so selflessly and happily support the club in any way. To 
Mari and Marja van der Lee, for all the effort you put in De Waterman scuba 
diving club. The annual scuba dive trips you organised were always rewarded with 
lasting memories, and, of course, cooling down in the snow on the annual ski trips 
together with the rest of the van der Lee family to Austria. You have forever 
added meaning to my definition of ‘gezelligheid’. 
To my dear friends Ralph Coolen, Erik van de Lee, Tiemco Nelissen, Andy 
Ouwerkerk, David Strijbos, and Rob Wissenburg. More than once I had to cancel 
planned social events with you to get to where I am now, somehow you forgave 
me every time. I could always rely on you to bring me down-to-earth again with 
your sobering remarks. Thank you for sticking with me all these years.
Dhanyabaad Basanta, Meela, and Prayash Shakya for making me feel included 
in a family a world apart. I wish we will soon be able to meet in-person and outside 
the confinements of video calling.
To my family Willebrord, Diny, Geert van de Wiel, Wilma, Rob, Matt, and Luke 
van Dijk. Papa en mama, bedankt voor jullie onuitputtelijke steun en vertrouwen 
in mij door de jaren heen. Bedankt dat jullie letterlijk altijd voor iedereen 
belangeloos en onbaatzuchtig klaar stonden. Jullie hebben mij vele levenslessen 
geleerd, ook al wilde ik er niet altijd naar luisteren. De vele boeren wijsheden 
die jullie vaak probeerden over te brengen aan ons hebben zeker bijgedragen 
aan de kwaliteit van dit proefschrift. Papa, bedankt dat je na mijn ziekzijn vaak 
vertelde “leer maar goed door, want jij kan geen timmerman worden”, die woorden 




mijn academische carrière. Mama, bedankt voor alle keren dat je een luisterend 
oor bood wanneer ik het nodig had. The Gurt en Wimla, ik kan mij geen betere 
brussen bedenken dan jullie. Jullie staan ook echt altijd voor mij klaar en kennen 
geen lengtes van opgeven om elkander te helpen. Wij zijn hechter geworden door 
alles wat we samen hebben meegemaakt. Zonder jullie steun en misschien ook 
wel opvoeding, ik ben tenslotte ‘de klène’, zou ik niet zijn wie ik nu ben. Rob, ik ben 
blij dat jij goed voor mijn grote zus zorgt. Samen met jullie lieve Matt en Luke 
vormen jullie een prachtig gezin. Ik hoop dat jullie een goede toekomst tegemoet 
gaan.
Dhanyabaad my maya, dhanyabaad Pallavi. We were together when the world 
seemed to be falling apart around us, but together we were and that made all the 
difference. Thank you for being a shining guiding light in the darkest of days, and 
thank you for making bright days so much brighter. Thank you for teaching me a 
different perspective on western society from your own cultural identity. Thank 
you for your ever-present kindness and generosity. Thank you for your radiating 
written words in poetry and stories, and your continuous and unwavering support 
that helped me cover the final stretch of my PhD journey. Whatever the future 
may bring us, knowing we may face it together makes it all the brighter. I can’t wait 
to dive into new adventures with you. Ma timilai maya garchu.
